

Data-adaptive SNP-set-based Association Tests of Longitudinal Traits

Yang Yang, M.S  
The University of Texas  
School of Public Health, 2014

Dissertation Chair, Peng Wei, PhD  
Minor Advisor, Alanna C. Morrison, PhD  
Breadth Advisor, Yun-Xin Fu, PhD  
External Advisor, Han Liang, PhD

# Contents

<b>1</b>	<b>Background</b>	<b>5</b>
1.1	Gene-based association tests . . . . .	6
1.2	Longitudinal study design and analysis strategy in GWAS . . . . .	11
1.3	Gene-set/Pathway based association tests . . . . .	18
<b>2</b>	<b>Public Health Significance</b>	<b>26</b>
<b>3</b>	<b>Declaration on Human Subjects</b>	<b>27</b>
<b>4</b>	<b>Specific Aims</b>	<b>27</b>
<b>5</b>	<b>Methods</b>	<b>29</b>
5.1	Overall Study Design . . . . .	29
5.1.1	Simulation studies . . . . .	29
5.1.2	Real data application . . . . .	29
5.2	Methods for Aim 1(a): To develop data-adaptive SNP-set based association tests for longitudinal data analysis within the Generalized Estimating Equations (GEE) framework for common variants . . . . .	32
5.2.1	Statistical Modeling . . . . .	32
5.2.2	Methods for Simulation Settings . . . . .	42
5.2.3	Plan for Simulation Studies . . . . .	46
5.3	Methods for Aim 1(b): To develop data-adaptive SNP-set based association tests for longitudinal data analysis within the Generalized Estimating Equations (GEE) framework for rare variants . . . . .	50

5.3.1	Statistical Modeling . . . . .	50
5.3.2	Methods for Simulation Settings . . . . .	51
5.3.3	Plan for Simulation Studies . . . . .	51
5.4	Methods for Aim 2: To develop the pathway-based data-adaptive association tests for longitudinal data analysis . . . . .	54
5.4.1	Statistical Modeling . . . . .	55
5.4.2	Methods for Simulation Settings . . . . .	56
5.4.3	Plan for Simulation Studies . . . . .	57
5.5	Methods for Aim 3: To develop the software package for method implementation	57
5.6	Methods for Real Data Application for Proposed Aims . . . . .	58
<b>References</b>		<b>61</b>

# List of Tables

1	Sample Table of Type I error Benchmark among tests . . . . .	48
2	Sample Table of Type I error Benchmark among tests using simulation-based method in RV analysis. mvn.UminP: UminP calculated by approximating a MVN distribution; UminP: UminP method calculated by simulation-based method. . . . .	52

# List of Figures

1	<b>Examples of competitive approach and self-contained approach based testings using Fisher’s exact test as a demonstration</b> (A). Example of competitive approach; (B). Example of self-contained approach. This figure is adopted from [Fridley and Biernacka, 2011]. . . . .	21
2	<b>Types of pathway association tests in GWAS.</b> (a). Categorization based on data input type; (b). Categorization based on hypothesis testing. This figure is adopted from Wang et al (2010) [Wang et al., 2010a]. . . . .	23
3	<b>ARIC Cohort Characteristics by Gender or Race.</b> Table adopted from the ARIC website . . . . .	31

# 1 Background

Genome-wide association studies (GWASs) have been popular since 2007. Hundreds of GWASs have been published already (A Catalog of Published Genome-Wide Association Studies: <http://www.genome.gov/26525384>). The most popular approach in GWAS is to test the association with complex traits on single nucleotide polymorphism (SNP), also known as single nucleotide variant (SNV), one by one, then select the SNVs that meet a stringent significance level after multiple testing correction, such as the Bonferroni and false discovery rate (FDR) methods [McCarthy et al., 2008, Hirschhorn and Daly, 2005]. However, this strategy will suffer from low power when the minor allele frequency (MAF) of the SNV is low (between 1% and 5%), and as a result the signals contained within the low MAF SNVs are hard to detect [Sham and Purcell, 2014]. In addition, the usual regression coefficient estimate of SNV becomes unstable due to the small number of minor allele counts and the coefficient estimate's variance becomes very large [Sham and Purcell, 2014]. It will become an even more severe problem for rare variants (RVs) analysis. RVs are usually defined as SNVs with MAF below 1% [Bansal et al., 2010]. In spite of their extremely low MAF, RVs' important role in conferring disease risk cannot be underestimated. Due to the constraint of purifying selection, causal and functionally deleterious variants are often RVs. In turn, they typically have larger effect sizes than common variants [Fu et al., 2013, Bansal et al., 2010, Sham and Purcell, 2014, McCarthy et al., 2008]. Therefore, developing new association tests tailored to low MAF SNVs and RVs has been a very active research area in recent years. Due to the nature of low MAF, either increasing the total sample size or aggregating information across multiple variants in an analysis set (for example gene) is expected to achieve a practically acceptable power [Capanu et al., 2011, Basu and Pan, 2011, Bansal et al., 2010, Sham and Purcell, 2014]. As increasing the sample size is usually expensive and demanding, SNP-set or gene-set based association tests pooling together information have been the major research directions [Ye and Engelman, 2011, Pinto et al., 2010, Sham and Purcell, 2014].

Sets of SNVs can be defined by gene boundaries (i.e., gene-based) or sliding windows; sets of genes can be defined by Gene Ontology terms, protein-protein interactions, canonical genetic signaling pathways or gene expression networks as examples. [Sham and Purcell, 2014, De la Cruz et al., 2010, Weng et al., 2011, Wang et al., 2010a, Wei et al., 2012].

## 1.1 Gene-based association tests

A large number of gene-based association tests (mainly designed for RVs) have been proposed in recent years. The earliest methods include the cohort allelic sums test (CAST)[Morgenthaler and Thilly, 2006] and the combined multivariate and collapsing (CMC) method [Li and Leal, 2008]. Afterward, more advanced tests were proposed. Those methods can be classified into major groups as follows.

A very famous category of these methods is the so-called “burden test” or “sum test”, such as a weighted sum statistic (WSS) [Madsen and Browning, 2009], which uses MAF based weighting scheme to combine the test statistics from multiple SNVs in a region, with the assumption that all the alleles to be deleterious. WSS is also known as Madsen and Browning test (MB test). Many other tests within the “burden test” category inherited and improved the WSS performance in some scenarios [Hoffmann et al., 2010, Zhang et al., 2010b, Ionita-Laza et al., 2011, Feng et al., 2011]. Such improved “burden tests” includes the sib-pair and odds ratio weighted sum statistics (SPWSS, ORWSS) [Zhu et al., 2010, Feng et al., 2011]; the replication-based test (RBT) [Ionita-Laza et al., 2011] which is built on WSS with the aim to be less sensitive to the presence of both risk and protective effects in a genetic region of interest; the yet another weighted-sum test with a “step-up” approach to choose the “best” combination of rare variants into a single aggregated group [Hoffmann et al., 2010]; the MB test with approximately optimal collapsing (AOC) method [Zhang et al., 2010b]; a data-driven P-value Weighted Sum Test (PWST) [Zhang et al., 2011] which used both significance and direction of individual variant effect from single-variant analysis to calculate a

single weighted sum score.

Another major category of gene-based association tests is the so-called “variance-component test”, which can be formulated as testing on a variance component in a random-effects (R-E) model. These tests include the Sum of Squared U-statistics test (SSU) [Pan, 2009], which is equivalent to a variance-component test; the C-alpha test [Neale et al., 2011], which handles RVs with mixed effect directions well but is not able to adjust for covariates (such as the principal components used to correct for population stratification confounders); the kernel machine regression (KMR) method [Wu et al., 2010, Kwee et al., 2008], which provides the flexibility of choosing different kernel functions  $h(\cdot)$  to measure the genomic similarity between the genotypes of subject  $i$  and  $j$ . It then regresses response on the specified kernel functions (if linear kernel, it is equivalent to the SSU test [Pan, 2009]); the widely used sequence kernel association test (SKAT)[Wu et al., 2011], which up-weights the SNVs with lower MAFs and assumes the effect of variants are independently and identically distributed with an arbitrary distribution of mean 0 and variance  $\tau^2$ ; the SKAT-O [Lee et al., 2012b, Lee et al., 2012a], which is a weighted linear combination of a burden test and the SKAT variance component test; the adjusted-SKAT [Ouakacha et al., 2013], which allows the variant effects to have an equal correlation  $\rho$  besides the usual assumption in SKAT; the GEE-based linear kernel machine SNP set association test [Wang et al., 2013] which is very closed to the SSU test.

The collapsing-based test inherited the idea from CMC/CAST method, and this type of tests is actually closely related to “sum test”. Here are a few most representative methods: the RARECOVER algorithm [Bhatia et al., 2010], which is a model-free method, collapses only a subset of the variants in a region to achieve the strongest association with a phenotype; the kernel-based adaptive cluster (KBAC) method [Liu and Leal, 2010], comparing the difference of weighted multi-site genotype frequencies between cases and controls; the rare variant weighted aggregate statistic (RWAS) method [Sul et al., 2011], which groups rare variants and computes a weighted sum of differences between case and control mutation counts.



Lasso and group-penalized regression based methods incorporated a mixture of group Euclidean penalties and single-predictor penalties (lasso) into linear or logistic regression [Zhou et al., 2010, Kim et al., 2014]. Group penalties are applied to SNVs within a single gene or within several genes in a pathway, while single-predictor penalties are applied at the single SNV level. The authors developed the coordinate descent algorithms that allow exceptionally fast computation and permit the optimal tuning of the penalty constant by cross-validation method.

Functional linear models (FLM) and (smoothed) functional principal component analysis (FPCA) based association tests [Luo et al., 2011, Luo et al., 2012b, Luo et al., 2012a, Fan et al., 2013] treated a chromosome as a continuum, on which variants identified from next-generation sequencing platform approximately evenly distributed. For FLM methods, the authors incorporated the genomic position  $t$  into the penalized regression equation for both genotype function and coefficient function, and then used basis function expansion method to solve the FLM. For FPCA methods, the authors incorporated the genomic position  $t$  into the eigenfunction for both genotype function and weight function, and then used either discretization method or basis function expansion method to solve the eigenfunction. If smoothing was used, the smoothing parameter  $\lambda$  was chosen by cross validation. The statistics from both FLM and FPCA follow the central  $\chi^2$  distribution.

Adaptive or hybrid tests combined the advantages from at least two major categories above to make the new test more data adaptive and more powerful. A few most representative methods are as follows: The EREC method [Lin and Tang, 2011] builds a general framework for association testing, which combines strength from MB test and variable-threshold (VT) test [Price et al., 2010] to form the most powerful test by setting the weight function  $\epsilon$  proportional to the set of estimated regression coefficients  $\hat{\beta}_t$  in the test statistic. A data adaptive test combines the score test, SSU test and Sum test’s advantages [Pan and Shen, 2011]. An exponential combination (EC) framework for set-based association tests [Chen et al., 2012] features with the sum of exponential statistics (statistics should follow either independent normal or independent chi-square distribution). The sum of exponential statistics are para-

metric and standardized from previous MB test and C-alpha test. A robust and powerful test uses Fisher’s method to combine linear and quadratic statistics [Derkach et al., 2013]. A unified mixed-effect model [Sun et al., 2013] tests both group effect equal to 0 and variance component equal to 0. It includes both burden and SKAT tests as special cases by embedding the variant functional information and allowing a variant specific random effect in the model.

There are other miscellaneous tests. Some of them can be classified into more than one category mentioned above, thus I include them here as well as other miscellaneous tests. A variable-threshold (VT test) approach [Price et al., 2010] computes z-score  $z(T)$  for each different MAF threshold  $T$ , defines  $z_{max}$  as the maximum z-score across values of  $z(T)$ , and finally assesses the statistical significance of  $z_{max}$  by permutations on phenotypes. A data-adaptive sum test (aSum) is capable of handling both deleterious and protective effects and allowing collapsing common variants (CV) into the test [Han and Pan, 2010]. A probabilistic disease-gene finder employs an aggregative variant association test that combines both amino acid substitution and allele frequencies as implemented in VAAST [Yandell et al., 2011] and the later improved version VAAST 2 [Hu et al., 2013]. The weighted score test [Cai et al., 2012] up- or down-weights the contribution from each member of the marker-set based on the Z-scores of their effects.

For a detailed comparison among and discussion of some of these tests, Basu and Pan have done a very comprehensive review and simulation-based benchmark [Basu and Pan, 2011]. Another comprehensive review can be found in [Bansal et al., 2010]. Recently Pan et al. also did a comparison of several latest methods including the PWST, EREC, aSSU, SKAT-O and their newly proposed aSPU method [Pan et al., 2014].

Due to the complexity of genetics association with a phenotype, for example, specific association effect direction and size, a given test favoring one scenario may or may not perform well in other scenarios [Pan, 2009, Derkach et al., 2013, Pan et al., 2014, Sun et al., 2013].

In other words, there is no single test that is the most powerful in all testing scenarios. Therefore, there have been a lot of efforts in developing adaptive/hybrid tests for RVs (for example, [Derkach et al., 2013, Chen et al., 2012, Han and Pan, 2010, Lee et al., 2012a, Lin and Tang, 2011, Pan and Shen, 2011, Sun et al., 2013, Zhang et al., 2011]). However, due to limited adaptability, for example, with a fixed set or pre-determined weights on individual RVs, these tests that combined some earlier tests' advantages (for example, the MB test, burden test and SKAT) are still not flexible enough to avoid power loss under some situations. Recently, a very prominent novel data adaptive test named aSPU has been proposed by [Pan et al., 2014]. It features the ability to achieve quasi-optimal power in all scenarios, such as varying number of SNVs within the genetic region of interest, varying ratio of signal SNVs to noise ones, same directional effect alleles or a mixed directional effect of both protective and deleterious alleles, varying allele frequencies and varying effect sizes. It maintains the most power as compared to other state-of-the-art tests in the presence of a large number of RVs within a genetic region that only contains a small portion of signals. This is usually the case in association studies based on whole-exome or whole-genome sequencing data [Pan et al., 2014]. In summary, the data-adaptive test is in general more powerful and robust than non-adaptive tests, and thus preferred in the future development of novel association tests. Among current data-adaptive association tests, the aSPU method is more adaptive than its predecessors. Hereby, I propose to extend the aSPU framework from the cross-sectional data scenario to the longitudinal data scenario. I also propose a few aSPU "variant" tests within the aSPU tests family. These aSPU 'variant' tests combine strength from the Score test and hence they are more robust in maintaining a higher power in almost all scenarios.

## 1.2 Longitudinal study design and analysis strategy in GWAS

### Comparison between longitudinal studies and cross-sectional studies

I first introduce two linear models for cross-sectional studies and longitudinal studies respectively. In a cross-sectional study ( $n_i = 1$ ) we are restricted to the model

$$Y_{i1} = \beta_C x_{i1} + \epsilon_{i1}, \quad i = 1, \dots, m, \quad (1)$$

where  $Y$  represents the quantitative trait,  $x$  represents the covariate,  $i$  represents the  $i$ th subject,  $j$  represents the  $j$ th measurement,  $n_i$  represents total measurement number for  $i$ th subject. Therefore,  $Y_{i1}$  represents the  $i$ th subject's trait measured at baseline while  $x_{i1}$  represents the  $i$ th subject's covariate measured at baseline. Furthermore,  $\beta_C$  represents the difference in average  $Y$  across two sub-populations (samples) which differ by one unit in  $x$ . With repeated measurements, the above linear model can be extended to

$$Y_{ij} = \beta_C x_{i1} + \beta_L (x_{ij} - x_{i1}) + \epsilon_{ij}, \quad i = 1, \dots, m; \quad j = 1, \dots, n_i \quad (2)$$

[WARE et al., 1990]. Now  $\beta_C$  still represents the time-averaged cross-sectional difference while  $\beta_L$  is interpreted as the expected change in  $Y$  over time per unit change in  $x$  for a given subject. The inference about  $\beta_C$  is a comparison of individuals with a particular value of  $x$  to other individuals with a different value of  $x$  at baseline. In contrast, the parameter estimation of  $\beta_L$  is by comparing a person's responses at two times, assuming that a person's  $x$  changes with time.

Based on above formula, we can better explain the merits of longitudinal studies over cross-sectional studies. Longitudinal studies allow us to estimate both the cross-sectional difference ( $\beta_C$ ) and the rate change over time ( $\beta_L$ ), the latter of which cross-sectional studies cannot estimate. Even when  $\beta_C = \beta_L$ , that is only time-averaged cross-sectional difference exists, longitudinal studies tend to be more powerful than cross-sectional studies. This is due to

the fact that in longitudinal studies, each person can be thought of serving as his/her own control. For most outcomes  $Y$ , there is considerable variability across individuals due to the influence of unmeasured characteristics such as genetic make-up, environmental exposures, personal behaviors/habits, and so forth. While these factors tend to persist over time for the same individual, their influences are canceled in the estimation of the  $\beta_L$  or equivalently here the  $\beta_C$ , and thus lead to more accurate estimate (with smaller variance). Another merit of the longitudinal study is its ability to distinguish the degree of variation in  $Y$  across time for one subject from the variation in  $Y$  across subjects. With repeated measurements, we can borrow strength across time for the same person of interest as well as across individuals. If there is little variation across subjects, one subject's estimate can rely on data from others as in the cross-sectional case. However, if the variation across individuals is large, we might prefer to use more data for the same individual across time. Last but not least, with longitudinal studies, we can estimate a person's current and future outcomes.

In my dissertation, I will mainly study the scenario under  $\beta_C = \beta_L$  for longitudinal association test. I assume the SNPs in a region contribute to the outcome  $Y$  as the main effect only and the fixed effect remains the same across time ( $\beta_C = \beta_L$ ). There is more to explain here about the efficiency of the longitudinal study. Let  $e = Var(\hat{\beta}_L)/Var(\hat{\beta}_C)$  be the specific measure of efficiency. Apparently, the smaller the value of  $e$ , the greater is the information gained by taking additional measurements across time on each person. The value of  $e$  depends on a number of factors, including correlation structure  $R$  (for example, compound symmetry or auto-regression), number of measurements ( $n_i$ ), magnitude of within-subject correlation ( $\rho$ ) and the ratio  $\delta$  of within-subject variation in  $x$  to between-subjects variation in  $x$  at baseline. In general, increasing  $n_i$  (for example, more measurements) and increasing  $\delta$  (for example, uneven measurement intervals) will lead to a smaller  $e$  under the scenario  $\beta_C = \beta_L$ . Besides, except when  $\delta$  is small and  $\rho$  is high at the same time, there is much to be gained by conducting longitudinal studies even when the number of repeated observations  $n_i$  is as small as two according to [Diggle et al., 2002].

Under different hypothesis testing scenarios, the identified significant signal loci from a longitudinal study may be the **same** or **different** from a comparable cross-sectional study. In the GWAS settings, the cross-sectional study always tests the SNP main effect ( $\beta_{main}$ ), and this will equate the longitudinal study with **only time-averaged SNP main effect** (i.e.,  $\beta_C = \beta_L$  in Equation 2). However, when the longitudinal study includes **the additional SNP  $\times$  time interaction term**, either joint testing both of the main effect and interaction effect equal to 0 or individual testing either effect equal to 0 will possibly lead to different significant loci from the corresponding cross-sectional study.

### Factors that influence the statistical power in longitudinal studies

In any study, investigators must provide the following quantities to determine the power  $P$ , including the Type I error rate ( $\alpha$ ), smallest meaningful difference ( $d$ ) to be detected, sample size ( $n$ ), variance ( $\sigma^2$ ) in response variable. In longitudinal studies, there are several additional factors to consider, including the number of repeated observations per person ( $n_i$ ) and the correlation among the repeated observations within the same person ( $\rho$ ). Let us briefly describe the relationship between these quantities and the power  $P$ : increasing  $\alpha$  will increase  $P$ ; increasing  $d$  will increase  $P$ ; increasing  $n$  will increase  $P$ ; reducing  $\sigma^2$  will increase  $P$ ; increasing  $n_i$  will increase  $P$ . For  $\rho$ , the relationship with  $P$  is not fixed but depends on which hypothesis is tested. In the  $\beta_C = \beta_L$  scenario, we are testing the time-averaged (group) main effect. An **decreasing**  $\rho$  will lead to a larger power. In contrast, in the  $\beta_C \neq \beta_L$  scenario when we are testing the slope effect  $\beta_L$ , an **increasing**  $\rho$  will lead to a larger power in testing the  $\beta_L = 0$ , that is the rate change over time equal to 0. This, at the first glance, seems counter-intuitive but is indeed reasonable. In the  $\beta_C = \beta_L$  scenario, the parameter of interest is the expected average of the  $Y$ 's for individuals in a group (i.e., the  $\beta_C$ ). A decreased  $\rho$  leads to an effectively larger sample size (within-subject measurements are more distinct), which in turn results in a smaller variance of  $\beta_C$  estimate. On the contrary, in the  $\beta_C \neq \beta_L$  scenario when we are testing  $\beta_L = 0$ , the rate of the change in  $Y$ , the contribution from each subject to the estimation of  $\beta_L$  is a linear contrast of the  $Y_{ij}$ .

The  $Y_{ij}$ 's variance is decreasing as  $\rho$  increases, i.e., within-subject measurements are more alike. Thus, an increasing  $\rho$  will lead to a larger power of testing the significant deviation from  $\beta_L = 0$ .

## Longitudinal studies in GWAS

Many GWASs have been performed in cohort studies, where phenotypes have been collected across multiple time points for each individual [Aulchenko et al., 2009, Ionita-Laza et al., 2007, Kamatani et al., 2010, Kathiresan et al., 2007, Sabatti et al., 2008]. However, the longitudinal information has not been fully utilized as the majority of the current association tests only considered either the baseline measurement or average measurement for each individual [Sabatti et al., 2008, Ionita-Laza et al., 2007, Kamatani et al., 2010, Kathiresan et al., 2007]. Compared with large number of GWASs, only very few studies involved longitudinal data analysis. One such study on smoking and nicotine dependence by [Belsky et al., 2013] has data from a four-decade longitudinal study. They used generalized estimating equation model to analyze the longitudinal data while accounting for correlation within subject. There are also several GWASs on Alzheimer's Disease involving the analyses of longitudinal phenotypic information collected at multiple time points [Wang et al., 2012, Melville et al., 2012, Silver et al., 2012]. Increased power from longitudinal study has been elucidated herein before, and recently this fact has been studied in depth by either simulation study and/or real data analysis in the GWAS settings [Xu et al., 2014, Furlotte et al., 2012]. Depending on the specific parameters settings in simulation studies (for example, correlation among repeated measurements, genetic variance, and environmental variance) and case by case for real data analysis (for example, the sample size and the SNV effect size), the power gain from longitudinal data analysis as compared to baseline data analysis can range from a moderate to a significant amount [Xu et al., 2014, Furlotte et al., 2012]. For example, the increased power was demonstrated from 0 to 0.4 with the maximal possible power value being 1 ideally, or the longitudinal analysis has as much as an eightfold gain in power over the baseline analysis. Therefore, a longitudinal study design and performing the longitudinal data analysis when

data are available are appealing in the GWAS settings.

### **Classical longitudinal data analysis methods**

Existing methods in longitudinal data analysis can be categorized into three main categories: 1, mixed-effect models; 2, marginal models with regression coefficients estimated by generalized estimating equations (GEE); 3, transition (Markov) models.

The mixed-effect model was first proposed in 1982 [Laird and Ware, 1982]. Mixed-effect model is an extension of a regression model to model longitudinal (correlated) data. It contains fixed effects and random effects, where random effects are subject-specific and are used to model between-subject variation and the correlation induced by this variation. Mixed-effect model is a two-stage method, which treats probability distributions for the response vectors of different individuals as a single family and the random-effects parameters which hold the same for the same individual as another distribution. Parameter estimation is usually done by restricted maximum likelihood (REML) and expectation-maximization (EM) algorithm [Laird and Ware, 1982].

Another major method, the marginal model with GEE was first proposed in 1986 [Zeger and Liang, 1986, Liang and Zeger, 1986]. It is an extension of the quasi-likelihood methods by Wedderburn [Wedderburn, 1974]. Rather than giving subject-specific (SS) estimates as in mixed-effect models, GEE gives population-averaged (PA) estimates by only describing the marginal expectation of the outcome variable as a function of the covariates and the variance of the outcome variable as a known function of the marginal expectation. By specifying a “working” correlation matrix, GEE method accounts for the correlation among the repeated observations for a given subject. Another appealing property of GEE is, by using the so-called sandwich variance estimator, the “working” correlation matrix does not need to be correctly specified in order to achieve consistent estimates. The generalized estimating equations are thus derived without specifying the joint likelihood function of a subject’s observations as needed in the SS model. The covariance structure across time is treated as a nuisance pa-



parameter. GEE can finally give consistent estimators of the regression coefficients by simply solving the score equations and doing iteratively reweighted linear regression.

The last major method, the transitional (Markov) model, describes the conditional distribution of each response  $y_{ij}$  as an explicit function of first  $q$  prior observations  $y_{ij-1}, \dots, y_{ij-q}$  from history response vector:  $H_{ij} = \{y_{ik}, k = 1, \dots, j-1\}$  and covariates  $x_{ij}$ . The integer  $q$  is referred as the order of the Markov models. With different link functions, Markov models can be applied to a range of GLMs as dealt in mixed models and marginal models. A few examples are linear link [Tsay, 1984], logit link [Cox and Snell, 1989, Zeger et al., 1985, Korn and Whittemore, 1979] and log link [Zeger and Qaqish, 1988]. Model fitting is straightforward for linear link, as in Gaussian autoregressive models, the full maximum likelihood estimation is available [Tsay, 1984]. For logistic and log-linear cases, the full likelihood is unavailable and the alternative is to maximize the conditional likelihood with GEE-like iterative weighted least square algorithm to solve the conditional score function and obtain consistent estimates [Cox and Snell, 1989, Zeger et al., 1985, Korn and Whittemore, 1979, Zeger and Qaqish, 1988].

Since transitional models are not widely used in the genetics association studies, we will omit its further discussion. Here we focus on the comparison between the mixed-effect and marginal-effect models. The application of GEE may be less appropriate when the time course of the response variable for each individual (subject-specific slope), for example, body mass index (BMI) measurements across several time points, is of primary interest, so as to the correlation parameters within the same subject [Zeger et al., 1988, Liang and Zeger, 1986]. The mixed-effect model could handle such inference of interests [Laird and Ware, 1982]. However, in the genetic association studies, subject-specific time course effect and/or within-subject correlation parameters are usually not of major interests. In other words, they are often treated as nuisance parameters. On the other hand, for association tests of a set of SNPs, the increased number of explanatory variables, for example, the SNVs on the right hand side (RHS) of the regression-like equation tend to consume a lot of degrees of freedoms

(dfs) and increase the difficulty of the optimization algorithm convergence. Large consumption of the dfs also leads to power loss and Type I error inflation, for example, excessive inflation in the Wald test [Guo et al., 2005, Pan, 2001, Shete et al., 2004]. Algorithm convergence difficulty is very often encountered in mixed model when it has a lot of covariates. For some extreme scenarios, for example, with a binary trait, the maximum likelihood estimator (MLE) of a regression coefficient of a RV does not exist if the minor alleles of this RV only appear in case or control, resulting in the convergence failure with an iterative algorithm to obtain the MLE [Zhang et al., 2014, Pan et al., 2014]. Another caveat of the mixed model is that mis-specification of the random-effects distribution and/or omitting part of the random-effects (for example, keeping only the random intercept in the mixed model when the random slope is also needed) will lead to excessive Type I error inflation [Litière et al., 2007, Xu et al., 2014]. Compared with the mixed-effect models, GEE models suffer much less from these problems. In particular, the GEE Score test is proved to be robust to Type I error inflation in the presence of a large number of covariates; upon usage of the so-called sandwich or robust covariance matrix, GEE will give consistent estimates even when the working correlation is misspecified, in contrast to the misspecified random effect in the mixed-effect models. In addition, GEE model fitting requires only evaluation under the null hypothesis, which greatly accelerates the computation. With regard to the power loss in the presence of an increased number of covariates (SNVs), a recently proposed data-adaptive association test within the GEE framework demonstrated convincing capability in maintaining a high power [Zhang et al., 2014, Pan et al., 2014]. Although this work is designed for a single cross-sectional trait or multiple cross-sectional traits, it can be extended to the longitudinal design scenario as detailed in Aim One below. Extending the gene-based association test to sets of multiple related genes could return more biological meaningful inference.

### 1.3 Gene-set/Pathway based association tests

In general, a gene set is a set of genes. A genetic pathway is a special gene set, which includes multiple genes interacting to form an aggregate biological function. Extending the gene-based association tests to sets of related genes could lead to more biological meaningful inference. By analyzing functional related genes together with the phenotype of interest, we are more likely to identify those signals hidden from or attenuated in single-gene based tests [for Blood Pressure Genome-Wide Association Studies et al., 2011, Hirschhorn, 2009, Zhong et al., 2010, Wang et al., 2010a]. Complex diseases are known to be influenced by a combination of genetic factors in addition to environmental factors, lifestyle factors, and their interactions [Hirschhorn and Daly, 2005, McCarthy et al., 2008]. Thus, by investigating the gene sets, more evidence contributing to a specific disease could be found. Another advantage of pathway-based association tests is similar to that of gene-based association tests: aggregating multiple genes/RVs, in contrast to testing each gene/RV separately, may boost the statistical power by combining moderate/weak signals. One convincing evidence is from the Cancer Genome Atlas project (TCGA: <http://cancergenome.nih.gov/>) in tumor sequencing studies. While only few oncogenes (for example, TP53 and EGFR) harbor many mutations, most others harbor few mutations in a tumor-dependent manner. Single gene-based association tests still suffer from low aggregated mutation frequency, whereas collectively, they have a much higher aggregated mutation frequency in a gene-set/pathway. Therefore, for some diseases such as cancer, a gene-set/pathway analysis by aggregating the somatic mutation information across genes will boost the statistical power, and is thus preferred.

Among association tests for sets of functional related genes, pathway-based association test is probably the most popular one [De la Cruz et al., 2010, Wang et al., 2010a]. Other types include Gene Ontology terms, protein-protein interaction, canonical genetic signaling pathways, gene expression networks as examples [Sham and Purcell, 2014, De la Cruz et al., 2010,

Weng et al., 2011, Wang et al., 2010a]. A “pathway” in the GWAS setting usually means a set of genes involved in the same biological function or process, for example, apoptosis. Some commonly used public pathway and gene-set databases/repositories include Kyoto Encyclopedia of Genes and Genomes (KEGG) [Ogata et al., 1999], BioCarta [Nishimura, 2001] and Gene Ontology [Ashburner et al., 2000]. KEGG and BioCarta provide manually curated pathways in different biological processes, whereas Gene Ontology mainly contains computational annotations for human genes. Several commercialized databases are also available including Ingenuity Pathway Analysis (IPA) and MetaCore from GeneGo. They combine the manually curated evidence, literature review and algorithm predicted results. There are also other specialized pathway databases, such as Science Signal Transduction Knowledge Environment [Gough, 2002] and Nature Pathway Interaction Database [Schaefer et al., 2009], both of which manually curated the cell signaling pathways; the MetaCyc database [Karp et al., 2002] and BioCyc database [Caspi et al., 2008], both of which contain metabolic pathways. In summary, there are abundant existing biological pathway databases, which will facilitate the pathway-based association study analysis.

### **Major classes of pathway-based association tests**

Depending on the null hypothesis to be tested, pathway-based association tests can be categorized into two major classes: self-contained approach and competitive approach [Goeman and Bühlmann, 2009, Liu et al., 2007, Nam and Kim, 2008, Wang et al., 2010a, Fridley et al., 2010, Fridley and Biernacka, 2011]. Self-contained (a.k.a. Constrained) approach hypothesizes there is no gene in the gene set associated with the phenotype, while competitive approach hypothesizes the same level of association of a gene set with the given phenotype as the complement of the gene set. Figure 1 illustrates the hypothesis testing difference between the two classes of approaches.

Competitive methods usually start with identifying SNPs/genes that are significantly associated with a phenotype, and then evaluate whether the significantly associated SNPs tend to be enriched in a predefined gene-set/pathway. These methods are called ‘competitive’ because they compare the frequency of significantly associated SNPs in a particular

set of genes/pathway with the frequency of significant associations among all genes not in the set [Fridley and Biernacka, 2011]. Representatives of competitive approach are gene set enrichment analysis (GSEA) [Subramanian et al., 2005], which is based on the Kolmogorov-Smirnov test and DAVID [Dennis Jr et al., 2003], which uses a modified Fisher’s exact test. In contrast, self-contained approach considers the null hypothesis that no SNPs/genes in the gene-set of interest are associated with the trait versus the alternative hypothesis that some SNPs/genes in the gene-set are associated with the trait. Methods in the self-contained class are more flexible. Their statistical significance can be assessed (1) by the deviation from the expected number of significant SNPs under the null hypothesis of no association between the phenotype and the gene-set/pathway, (2) by computing the association p-values for each SNP in a gene-set/pathway, followed by testing whether the difference between the observed distribution of the SNP-level p-values and the expected distribution under the null hypothesis is significant, (3) by modeling the effect of gene via aggregating multiple SNPs, followed by modeling the effect of gene-set via aggregating multiple relevant genes, or (4) by directly modeling the effect of gene-set by aggregating the SNPs within the gene-set, skipping the gene-level statistics.

## A. Competitive Approach

### Example A:

	Significant	Not Significant		
SNP in gene set G	20	80	100	• 20% of SNPs within G significant
SNP outside gene set G	100	400	500	• 20% of SNPs outside of G significant
	120	480	600 SNPs	• P = 0.55 for Fisher's exact test of the competitive hypothesis
				• No evidence of enrichment

### Example B:

	Significant	Not Significant		
SNP in gene set G	40	60	100	• 40% of SNPs within G significant
SNP outside gene set G	100	400	500	• 20% of SNPs outside G significant
	140	460	600 SNPs	• P < 0.001 for Fisher's exact test of the competitive hypothesis
				• Evidence of enrichment

*\*Note that the statistical test applied here assumes independence of p-values, which is an invalid assumption in the presence of LD. Here this simple test is only used to illustrate the competitive hypothesis.*

## B. Self-contained Approach

Number of SNPs in gene set G significant with $p < 0.05$			
	Significant	Not Significant	
Observed	20	80	• 20% of SNPs within G significant.
Expected	5	95	• Under the null hypothesis, expect 5% of the SNPs to be significant.
			• P = 0.002 for Fisher's exact test of the self-contained hypothesis.
			• Evidence of association of the gene set with the trait.

*\*Note that the statistical test applied here assumes independence of p-values, which is an invalid assumption in the presence of LD. Here this simple test is only used to illustrate the self-contained hypothesis.*

Figure 1: Examples of competitive approach and self-contained approach based testings using Fisher's exact test as a demonstration (A). Example of competitive approach; (B). Example of self-contained approach. This figure is adopted from [Fridley and Biernacka, 2011].

The self-contained approaches have a few edges over the competitive approach. A limitation of the competitive approaches is that they cannot be applied to studies of candidate gene-sets for which only SNPs in the candidate gene-sets have been genotyped but not in the complemented ones. The reason is straightforward: competitive approaches require a comparison

between many different pathways. On the other hand, self-contained approaches require only genotypes from a collection of candidate genes, which in turn enable the genome-wide studies, candidate gene studies, pathway studies or specific disease gene group studies. Specific disease gene group studies are very popular, for example, the cardiovascular diseases, the metabolic traits and the autoimmune diseases. These studies usually come with the disease-specific genotyping platforms, for example, the ImmunoChip [Cortes and Brown, 2011], the metabochip [Voight et al., 2012] and the CVD35/cardiovascular-IBC-array [Cheng et al., 1999, Keating et al., 2008]. The self-contained approaches have also been reported to be more powerful than the competitive approaches [Goeman and Bühlmann, 2007]. This follows immediately from the fact that the self-contained null hypothesis is more restrictive than the competitive null hypothesis, as noted before. As a result, a self-contained test will almost always reject the null hypothesis for more gene-sets than a competitive null. Nevertheless, some drawbacks of the self-contained approach have been reported, for example, the global inflation of test statistics is often observed or not adequately adjusted, finally leading to an inflated Type I error [Wang et al., 2007, Goeman and Bühlmann, 2007, Fridley et al., 2010].

Additionally, based on the input data type, the pathway-based tests can be broadly classified into two categories: those that require raw genotypes and those that require a list of SNP p-values. The first approach, 'raw genotype approach', requires raw SNP genotypes as input to derive gene-level and pathway-level test statistics, whereas the second approach, 'p-value enrichment approach', requires a list of pre-calculated SNP p-values to determine whether a specific group of p-values for SNPs (or genes) is enriched with association signals. The 'p-value enrichment approach' only requires pre-computed SNP p-values and it greatly saves the labor in coordinating data analysis and data sharing, however, the 'raw genotype approach' provides more flexible solutions such as multi-SNP tests which requires individual genotype data to derive gene-level test statistics (some of these methods pool all the SNPs in a pathway together without calculating test statistics for pathway gene members). Another example is those methods based on single-SNP p-values but require raw genotype data to execute

phenotype permutation-based test. In this way, those methods can come up with a more unbiased pathway enrichment score. The 'raw genotype approach' is also less biased, such as it can adjust for gene length, the distance threshold to assign SNPs to nearby genes and the way to summarize gene-level test statistics. The graphic demonstration of the method categorization is shown in Figure 2.




Figure 2: **Types of pathway association tests in GWAS.** (a). Categorization based on data input type; (b). Categorization based on hypothesis testing. This figure is adopted from Wang et al (2010) [Wang et al., 2010a].

## Existing pathway-based association tests

There are several popular existing methods for pathway-based association tests. The earliest method is the gene-set enrichment analysis (GSEA) algorithm, a method adapted for pathway-based analysis of GWAS data. It calculates a weighted Kolmogorov-Smirnov-like running-sum statistics and uses a permutation-based procedure to evaluate the statistical



significance [Wang et al., 2007]. The GSEA-SNP, a modification of Wang et al’s GSEA [Wang et al., 2007], uses the max-test and all SNPs in a gene [Holden et al., 2008]. The iGSEA4GWAS, first permutes the SNP labels (for example, the SNP rs id), then assigns SNPs to genes, and finally calculates the modified GSEA enrichment score [Zhang et al., 2010a]. The Gene Set Analysis (GSA-SNP), computes the gene-level test statistic based on the SNP with the minimum P-value (or the second minimal), followed by gene-set-level test using either a Z-test, maxmean test, or GSEA [Nam et al., 2010]. The Gene Set-based Analysis of Polymorphisms (GeSBAP), first calculates enrichment score using ranked gene list, then assigns the best SNP p-value to a gene, and finally uses Fisher’s exact test for the gene-set association [Medina et al., 2009]. De la Cruz et al (2010) proposed A modification of Fisher’s method for combining SNP P-values for gene-level or gene-set-level association [De la Cruz et al., 2010]. The gene set ridge regression in association studies (GRASS), executes lasso regression (L1-norm) of eigenSNPs within each gene to achieve variable selection, while performing ridge regression (L2-norm) of eigenSNPs at the gene-set-level to achieve the shrinkage of gene effect (for example, disease odds ratio) estimates simultaneously [Chen et al., 2010a]. PLINK, a widely used software package in GWAS data analysis, provides an option to execute gene-set-level association analysis [Purcell et al., 2007]. The association list go annotator (ALIGATOR) method, a ‘p-value enrichment approach’ requiring only pre-computed SNP p-values, uses Fisher’s exact test on SNP with the minimum p-value for the gene-level association. It can correct for linkage disequilibrium (LD) between SNPs, various gene size, and multiple testing of nonindependent pathways [Holmans et al., 2009]. The SNP ratio test (SRT) method, tests the ratio of significant SNPs in a pathway and computes the empirical p-value based on permutation [O’Dushlaine et al., 2009]. The supervised principal component analysis, uses the Gumbel extreme value mixture distribution as test statistic’s null distribution. The test statistic is standardized for pathway size using a simulation procedure [Chen et al., 2010b]. The Prioritizing Risk Pathways fusing SNPs and pathways (PRP) method, executes the gene-level association test based on maximum

risk statistic, followed by mean risk approach to obtain gene-set-level risk statistic, then weights this statistic by specific pathway degree (that is, total edges in a pathway) and standardizes it to a zero dimension (that is, the minimal value is 0) [Chen et al., 2009]. Luo et al (2010) proposed three statistics to combine a set of dependent p-values of SNPs into an overall significance level for a gene, and then combined a set of dependent p-values of genes into an overall significance level for a pathway. The three statistics, which take into account the LD among SNPs or correlation among genes in the specific pathway, are linear combination test (LCT) asymptotically following normal distribution under null hypothesis, Quadratic test (QT) asymptotically following central Chi-square distribution under null hypothesis, and decorrelation test (DT) combining decorrelated individual statistics by Fisher’s combination test and asymptotically following a central Chi-square distribution under null hypothesis [Luo et al., 2010]. In addition, Peng et al (2009) developed four methods to combine a list of SNP p-values or gene-level p-values with the assumption that individual SNPs/genes are independent. These four methods are Fisher’s, Sidak’s, Simes’ and the FDR method [Peng et al., 2009]. The Gene-loci Set Analysis (GLOSSI) method, first uses the Cochran-Armitage trend test at single-SNP level assuming an additive SNP effect, then uses Fisher’s combination test to combine individual p-values of SNPs, and finally corrects the test statistics by Brown’s approximation to better control the Type I error [Chai et al., 2009]. An adaptive rank truncated product (ARTP) statistic, combines permutation-based SNP-level p-value to derive gene-level significance level and/or combines gene-level p-values to derive pathway-level significance level [Yu et al., 2009]. Detailed reviews about these and other pathway-based association tests can be found in [Tintle et al., 2011, Wang et al., 2010a, Fridley and Biernacka, 2011].

## 2 Public Health Significance

The majority of human diseases are complex diseases, for example, cardiovascular disease, type 2 diabetes, Alzheimer’s disease and autoimmune disease. These diseases have high incidence rate in the US and worldwide [Craig et al., 2008, Inzucchi et al., 2012, Go et al., 2013, Association et al., 2014, Benros et al., 2014]. The development of complex diseases involves genetic factors, environmental factors, behavior factors, and the interactions among them. In public health research, identification of the casual factors and the heritability of complex disease has always been a frontier topic. Researchers often first look for the genetic factors, followed by gene-gene and gene-environment interaction analyses. The GWASs have already identified more than 1000 genetic loci associated with many human diseases and traits [Hindorff et al., 2009]. These genetic loci have been validated by some validation procedures, such as replicate studies, meta analysis and wet lab experiments [Wang et al., 2005, Hirschhorn and Daly, 2005, McCarthy et al., 2008, Hindorff et al., 2009, Cantor et al., 2010].

The advent of the Next-Generation Sequencing (NGS) technique has brought human genetics to a new era [Ansorge, 2009, Metzker, 2009, Mardis, 2008, Shendure and Ji, 2008], and has the potential to explain some of the missing heritability via disease/trait-associated rare variants [Eichler et al., 2010]. Researchers have delivered tremendous efforts in developing powerful association tests either for common variants or rare variants, in gene-based and/or pathway-based manner as aforementioned. These tests are mainly designed for cross-sectional data analysis, which utilizes less information and is thus less powerful than longitudinal data analysis. Although some of the existing methods have the potential to be extended for longitudinal data scenario, the work has not been done yet. As the association pattern between variants and disease/trait is subtle and largely unpredictable, more and more novel “data-adaptive” association tests have been developed. The so-called “data-adaptive” test can maintain a high power for various real world data sets. In my dissertation, I will develop statistical methods that will provide researchers with more powerful and robust

data-adaptive association tests for either common variants (CVs) or rare variants (RVs) in the longitudinal data settings. Both gene-based and pathway-based test strategies will be implemented. Furthermore, an R package or independent Linux command-line based software implementing the methods will be released as part of the methodology development, which will greatly facilitate the research community to use the new methods in real data analysis. In conclusion, my dissertation work will provide useful methods and tools to identify the underlying genetic factors and explain the heritability of human complex diseases. In the long run, it may contribute to the prevention, diagnosis and cure of complex diseases.

### **3 Declaration on Human Subjects**

This dissertation study will focus on statistical method development. I will use the ARIC cohort data for method demonstration purpose. I will use the blood lipid phenotypes, covariates such as demographic variables, and genotype (GWAS and ExomeChip) in the ARIC data set. All data are pre-existing and de-identified. The IRB approval for the use of ARIC data set in my dissertation research has been obtained by my dissertation advisor, Dr. Peng Wei, under UTHealth IRB approval (HSC-SPH-13-0492).

### **4 Specific Aims**

As reviewed before, current association testing methods are mainly designed for cross-sectional data analysis, while many cohort studies have the longitudinal measurements which have not been fully utilized. For instance, the Atherosclerosis Risk in Communities (ARIC) study [Heiss, 1989] has multiple follow-up measurements across almost 30 years. Association tests that fully utilize the information across time points tend to achieve a higher power and identify more disease-associated loci [Furlotte et al., 2012, Xu et al., 2014]. As both the common variants (CV) and rare variants (RV) are important in identifying the disease at-

tributing genetic factors, a well-rounded association test should have the flexibility to work with either of them. It should also maintain a relatively high power in almost all scenarios encountered in real data analysis. In practice, it is hard to predict which specific method has the highest power and which methods suffer from a large power loss for a specific data set. To meet these urgent needs, I propose a powerful data-adaptive SNP-set based association test for the longitudinal data analysis, applicable to either CVs or RVs. The specific aims are as follows.

**Aim 1: To develop data-adaptive SNP-set based association tests for longitudinal data analysis within the Generalized Estimating Equations (GEE) framework.**

The proposed test, namely aSPU test, will have relatively high power in most data scenarios and avoid drastic power loss in any single data scenario, as compared to existing methods. This will be the first data-adaptive association test method for longitudinal data analysis. There are two **sub-aims**: **1(a)**. model development for common variants; **1(b)**. model development for rare variants.

**Aim 2: To develop the pathway-based data-adaptive association tests for longitudinal data analysis.** I propose to extend the proposed method in Aim 1 to the pathway-based association test version, namely Path-aSPU. It will work for either common variants or rare variants in a gene-set/pathway-based manner. Currently, there are no statistical models designed for pathway-based association test in longitudinal data settings, let alone the data-adaptive merit.

**Aim 3: To develop the software package for method implementation.** I will provide an R package or a Linux command-line based software program to enable convenient implementation of proposed methods. The package/software will be released to public (for example, CRAN) eventually.

## 5 Methods

### 5.1 Overall Study Design

#### 5.1.1 Simulation studies

I will first generate the simulated dataset for testing the performance of our proposed novel methods in Aim 1(a), Aim 1(b) and Aim 2. Specifically, I will generate the simulated genotypes within a gene, that is simulated CVs for Aim 1(a) and simulated RVs for Aim 1(b) and Aim 2. I will also generate the simulated longitudinal phenotype mimicking the real data, the ARIC cohort data, used for Aim 1 and 2. Additionally, for Aim 2, I will simulate the pathway containing multiple genes for testing the pathway-based association. For all simulations, I will refer to several literature [Pan et al., 2014, Basu and Pan, 2011, Pan and Shen, 2011, Han and Pan, 2010, Pan, 2009] and the ARIC data to set up the simulation parameters, thereby the simulated dataset will be more close to the real dataset. In the simulation studies for Aim 1 and 2, I will evaluate the proposed methods' performance on maintaining the nominal Type I error and a higher empirical power under different simulation scenarios. I will compare the proposed tests to a few existing methods to demonstrate the advantages.

#### 5.1.2 Real data application

After simulation studies, I will apply the proposed methods in Aim 1 and Aim 2 on the real dataset. A brief introduction to the real dataset is as follows.

The Atherosclerosis Risk in Communities Study (ARIC), sponsored by the National Heart, Lung, and Blood Institute (NHLBI), is a prospective epidemiological study conducted in four U.S. communities. ARIC is designed to investigate the causes of atherosclerosis and its clinical outcomes, the variation in cardiovascular risk factors, medical care, and disease by race, gender, location, and time. ARIC data include two parts: the Cohort Component and

the Community Surveillance Component.

The Cohort Component of the ARIC study, on which I will apply our proposed methods, began in 1987. Each of the four ARIC field centers (Washington County, MD; Forsyth County, NC; Jackson, MS; and Minneapolis, MN) randomly selected and recruited a cohort sample of approximately 4,000 individuals aged 45-64 from a defined population in their community. A total of 15,792 participants received an extensive examination, including medical, social, and demographic data. These participants were re-examined every three years with the first examination (baseline) occurring in 1987-89, the second in 1990-92, the third in 1993-95, and the fourth exam was in 1996-98. The fifth examination is farther apart from the previous screens and was finished during 2011-2013. A detailed description of the ARIC study design and methods was published elsewhere [Investigators et al., 1989].

As for real data application purpose for both Aim 1 and Aim 2, I will exclusively use the Caucasian samples ( $n = 11478$ ) in the ARIC cohort dataset. I will use lipid traits in the ARIC cohort as the response variables with longitudinal measurements. Candidate traits include four closely cardiovascular disease-related traits, which are total cholesterol (TC), High-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C) and triglycerides (TRG). For genotype data part, I will use the common variants for Aim 1(a) and the rare variants for Aim 1(b) and Aim 2. Both CVs and RVs are genotyped by ExomeChip platform [Grove et al., 2013] in the ARIC study. Through real data application, I will try to validate the reported risky loci for cardiovascular disease and identify potential novel loci, on a specific gene (Aim 1) or within a specific pathway (Aim 2). The method details for real data application is put below in Section 5.6.

A demographic introduction of the ARIC cohort data is shown in Figure 3

Cohort Characteristics			
Characteristics of ARIC Cohort at Baseline by Sex or Race			
Variable	WOMEN	MEN	
	(n=8710)	(7082)	
	Percent or Mean (SD)	Percent or Mean (SD)	
White	69%	77%	
Age 45-54	56%	49%	
55-64	44%	51%	
Family Income > \$25,000	53%	67%	
Glucose Diabetes (cut point=126)	12%	12%	
Current Smoker	25%	28%	
Usually Have Cough	12%	13%	
Hypertension (140/90 or meds)	35%	35%	
Rose Angina	6%	4%	
Major Q-wave	0.3%	0.6%	
Prior MI Reported	2%	8%	
Ever Exercise	60%	66%	
BMI (kg/m <sup>2</sup> )	28 (6)	27 (4)	
Cholesterol (mg/dl)	218 (43)	211 (40)	
HDL Cholesterol (mg/dl)	57 (17)	44 (14)	
Triglycerides (mg/dl)	124 (82)	142 (99)	
Fibrinogen (mg/dl)	308 (66)	298 (65)	
Factor VIIc	125 (31)	112 (26)	

Variable	White	Non-White
	(n=11478)	(4314)
	Percent or Mean (SD)	Percent or Mean (SD)
Women	53%	62%
Age 45-54	51%	58%
55-64	49%	42%
Family Income > \$25,000	72%	27%
Glucose Diabetes (cut point=126)	9%	20%
Current Smoker	25%	30%
Usually Have Cough	13%	11%
Hypertension (140/90 or meds)	27%	56%
Rose Angina	5%	4%
Major Q-wave	0.4%	0.4%
Prior MI Reported	5%	4%
Ever Exercise	70%	44%
BMI (kg/m <sup>2</sup> )	27 (5)	30 (6)
Cholesterol (mg/dl)	215 (41)	215 (45)
HDL Cholesterol (mg/dl)	50 (17)	55 (18)
Triglycerides (mg/dl)	138 (93)	114 (80)
Fibrinogen (mg/dl)	298 (62)	320 (72)
Factor VIIc	119 (29)	118 (31)

Figure 3: ARIC Cohort Characteristics by Gender or Race. Table adopted from the ARIC website



## 5.2 Methods for Aim 1(a): To develop data-adaptive SNP-set based association tests for longitudinal data analysis within the Generalized Estimating Equations (GEE) framework for common variants

### 5.2.1 Statistical Modeling

Suppose for each subject  $i = 1, \dots, n$ , we have  $k$  total longitudinal measurements  $y_i = (y_{i1}, y_{i2}, \dots, y_{ik})'$  with  $y_{im}$  as a element,  $p$  SNPs of interest as a row vector  $x_i = (x_{i1}, x_{i2}, \dots, x_{ip})$  with  $x_{ij}$  coded as 0,1 or 2 for the count of the minor allele for SNP  $j = 1, \dots, p$ , and  $z_i = (z_{i1}, z_{i2}, \dots, z_{iq})$  is a row vector for  $q$  variates. We assume common effect sizes (a.k.a., time-averaged group effect) of the SNPs and covariates on the longitudinal phenotype/trait measurements. Thus, we construct the design matrix for the SNPs and covariates as:

$$X_i = \begin{pmatrix} x_i \\ x_i \\ \vdots \\ x_i \end{pmatrix}, Z_i = \begin{pmatrix} 1 & z_i \\ 1 & z_i \\ \vdots & \vdots \\ 1 & z_i \end{pmatrix}$$

where  $x_i$  and  $z_i$  are row vectors of length  $p$  and  $q$  respectively.  $X_i$  is a  $k \times p$  matrix, and  $Z_i$  is a  $k \times (q + 1)$  matrix. Denote the regression coefficient  $\beta = (\beta_1, \beta_2, \dots, \beta_p)'$  and  $\varphi = (\varphi_1, \varphi_2, \dots, \varphi_{q+1})'$  for  $X_i$  and  $Z_i$  respectively. The marginal mean of each measurement,  $E(y_{im}|x_i, z_i) = \mu_{im}$  where  $m = 1, 2, \dots, k$  for  $k$  total measurements, or the vectorized format of all measurements,  $E(y_i|x_i, z_i) = \mu_i$ , relates to the SNPs and covariates through a generalized linear model (GLM):

$$g(\mu_i) = \eta_i = Z_i\varphi + X_i\beta = H_i\theta$$

with  $H_i = (Z_i, X_i)$ ,  $\theta = (\varphi', \beta')'$  and  $g(\cdot)$  as a suitable link function. For continuous outcome, an identity link is usually used.

The consistent and asymptotically Normal estimates of  $\beta$  and  $\varphi$  can be obtained by solving the GEE [Liang and Zeger, 1986]:

$$U(\varphi, \beta) = \sum_{i=1}^n U_i(\varphi, \beta) = \sum_{i=1}^n \left( \frac{\partial \mu_i}{\partial \theta'} \right)' V_i^{-1} (Y_i - \mu_i) = 0,$$

with

$$\frac{\partial \mu_i}{\partial \theta'} = \frac{\partial g^{-1}(H_i \theta)}{\partial \theta'}, V_i = \phi A_i^{\frac{1}{2}} R_w A_i^{\frac{1}{2}},$$

and

$$A_i = \begin{bmatrix} v(\mu_{i1}) & 0 & \cdots & 0 \\ 0 & v(\mu_{i2}) & 0 & 0 \\ \vdots & 0 & \ddots & \vdots \\ 0 & 0 & \cdots & v(\mu_{ik}) \end{bmatrix}$$

$\phi$  in  $V_i$  is the dispersion parameter in GEE and is usually treated as nuisance parameter.  $v(\mu_{im}) = \phi \text{Var}(y_{im} | x_i, z_i)$ .  $R_w(\alpha)$  is a working correlation matrix depending on some unknown parameter  $\alpha$ . For convenience, a working independence model with  $R_w = I$  is often used. With a canonical link function and a working independence model, we have a closed form of the U vector with two parts corresponding to SNPs and covariates, and its covariance

estimator:

$$\begin{aligned}
U &= (U'_{.1}, U'_{.2})' = \sum_i (Z_i, X_i)' (Y_i - \mu_i) \\
\tilde{\Sigma} &= \widehat{\text{Cov}}(U) = \sum_i (Z_i, X_i)' \widehat{\text{var}}(Y_i) (Z_i, X_i) = \sum_i (Z_i, X_i)' (Y_i - \hat{\mu}_i)(Y_i - \hat{\mu}_i)' (Z_i, X_i) = \begin{pmatrix} V_{11} & V_{12} \\ V_{21} & V_{22} \end{pmatrix}
\end{aligned} \tag{3}$$

where  $\hat{\mu}_i$  is an estimator of  $\mu_i$ ,  $\tilde{\Sigma}$  is an estimate of the covariance of score (U) vector.  $\tilde{\Sigma}$  is partitioned with the dimensions according to the score vector component  $U_{.1}$  and  $U_{.2}$  for  $\varphi$  and  $\beta$  respectively.

#### *Quantitative traits*

We use the identity link, i.e.  $g(\mu_{im}) = \mu_{im}$  and  $v(\mu_{im}) = \phi \times 1 = \phi$ . Then we have:

$$\begin{aligned}
U &= \sum_i (Z_i, X_i)' R_w^{-1} (Y_i - \mu_i) \\
\tilde{\Sigma} &= \sum_i (Z_i, X_i)' R_w^{-1} (Y_i - \hat{\mu}_i)(Y_i - \hat{\mu}_i)' R_w^{-1} (Z_i, X_i)
\end{aligned} \tag{4}$$

if the assumption of a common covariance matrices across  $Y_i$  for  $i$  is valid, for example for quantitative continuous traits study [Pan, 2001], we can adopt a more efficient covariance estimator:

$$\tilde{\Sigma} = \sum_{i=1}^n (Z_i, X_i)' \widehat{\text{var}}(Y_i) (Z_i, X_i) = \sum_{i=1}^n (Z_i, X_i)' \left( \sum_{i=1}^n \frac{(Y_i - \hat{\mu}_i)(Y_i - \hat{\mu}_i)'}{n} \right) (Z_i, X_i) = \begin{pmatrix} V_{11} & V_{12} \\ V_{21} & V_{22} \end{pmatrix}$$

which is used by default for its better finite-sample performance [Pan, 2001].

In my dissertation, I will **focus on** the case with quantitative traits, since they are most typical traits used as response variable in the longitudinal data analysis. Nevertheless, I introduce the strategy for binary traits below. In general, the only difference is the canonical

link function, with all other equations/formulas keep the same.

### *Binary traits*

For binary traits (trait value coded as 0 and 1), we use the logit link function so that  $g(\mu_{im}) = \log \frac{\mu_{im}}{1-\mu_{im}}$  and  $v(\mu_{im}) = \mu_{im}(1 - \mu_{im})$ . Additionally the  $(m, l)$ th element of  $\frac{\partial \mu_i}{\partial \theta'}$  is  $H_{i,ml}\mu_{im}(1 - \mu_{im})$  with  $H_{i,ml}$  as the  $(m, l)$ th element of  $H_i$ , which is the short notation for  $(Z_i, X_i)$ .

Then we have:

$$\begin{aligned} U &= \sum_{i=1} \left( \frac{\partial \mu_i}{\partial \theta'} \right)' V_i^{-1} (Y_i - \mu_i) \\ &= \sum_{i=1} \left( \frac{\partial \mu_i}{\partial \theta'} \right)' \phi A_i^{-\frac{1}{2}} R_w^{-1} A_i^{-\frac{1}{2}} (Y_i - \mu_i) \end{aligned}$$

and

$$\begin{aligned} \tilde{\Sigma} &= \sum_i \left( \frac{\partial \mu_i}{\partial \theta'} \right)' \phi A_i^{-\frac{1}{2}} R_w^{-1} A_i^{-\frac{1}{2}} (Y_i - \hat{\mu}_i) (Y_i - \hat{\mu}_i)' \phi A_i^{-\frac{1}{2}} R_w^{-1} A_i^{-\frac{1}{2}} \left( \frac{\partial \mu_i}{\partial \theta'} \right) \\ &= \begin{pmatrix} V_{11} & V_{12} \\ V_{21} & V_{22} \end{pmatrix} \end{aligned}$$

### *Several Existing Association Tests*

Our goal is to detect whether there is any association between the longitudinal trait and the SNPs via testing on hypothesis  $H_o : \beta = (\beta_1, \beta_2, \dots, \beta_p)' = 0$ . We have under the null hypothesis with  $g(Y_i) = Z_i\varphi$  to obtain  $\varphi$  and predict  $\hat{\mu} = g^{-1}(Z\hat{\varphi})$ . We hereby have score vector under the null hypothesis, with a working independence model, is:

$$U(\hat{\varphi}, 0) = (U'_{.1}, U'_{.2})' = \sum_{i=1}^n (U'_{i1}, U'_{i2})'$$

where

$$U_{.1} = \sum_i Z_i'(Y_i - \hat{\mu}_i), U_{.2} = \sum_i X_i'(Y_i - \hat{\mu}_i)$$

As  $U$  asymptotically follows a multivariate normal distribution under  $H_0$ , then the score vector for  $\beta$  also has an asymptotic normal distribution:

$$U_{.2} \sim N(0, \Sigma_{.2}), \Sigma_{.2} = \widehat{Cov}(U_{.2}) = V_{22} - V_{21}V_{11}^{-1}V_{12}$$

, where  $V_{xx}$  are defined in Equation 3.

- **The Wald Test:** The Wald Test known as  $T = \hat{\beta}' \text{cov}(\hat{\beta}) \hat{\beta}$  is most commonly used, where  $\hat{\beta}$  is the estimate of  $\beta$  after fitting the full GEE model with  $g(\mu_i) = Z_i\varphi + X_i\beta$ . Under  $H_0$ , we have  $T \sim \chi_p^2$ . The Wald test is more time consuming by fitting full model, may fail to converge with many SNPs put on RHS of the regression-like equation to test, and even worse, the type I error tends to inflate in such case [Pan et al., 2014, Zhang et al., 2014].
- **The Score Test:**  $T = U_{.2}'\Sigma_{.2}^{-1}U_{.2}$ , where  $U_{.2}$  and  $\Sigma_{.2}$  are discussed above; the statistic is asymptotically equivalent to the Wald test with the same null distribution  $T \sim \chi_p^2$ . Since we only need to fit the null model with covariates, it is computationally easier and less likely to have numerical convergence problems. More importantly, the score test controls the type I error well [Pan et al., 2014, Zhang et al., 2014].
- **The UminP Test:**  $T = \max_j \frac{U_{.2,j}^2}{\Sigma_{.2,jj}}$  for  $j \in 1, 2, \dots, p$ , of  $j$ th SNP effect. The  $\Sigma_{.2,jj}$  is the  $j$ th entry on the diagonal of  $\Sigma_{.2}$ . With  $\max T$ , we can get minimal p-value accordingly. An asymptotic multivariate normal distribution numerical integration based method provided a fast way to calculate its p-value [Pan et al., 2009, Pan, 2009]; alternatively, a simulation based method relying on the asymptotic normal distribution of the score vector can be used to calculate its p-value [Pan et al., 2014, Zhang et al., 2014]. Specifically, we first simulate the score vector  $U_{(b)} = (U_{(b).1}, U_{(b).2}, \dots, U_{(b).p})'$

from its null distribution  $U_{(b)} \sim N(0, \Sigma_{.2})$  for  $b = 1, 2, \dots, B$ , then calculate a total number of B null statistics:  $T^{(b)} = \max_{j=1, \dots, p} \frac{U_{(b),j}^2}{\Sigma_{.2,jj}}$ , and the p-value is calculated as  $\sum_{b=1}^B \frac{I(T^{(b)} \geq T) + 1}{B+1}$ .

With a working independence correlation matrix  $R_w = I$ , every element  $\frac{U_{.2,j}^2}{\Sigma_{.2,jj}}$  is equivalent to running the model on each single SNP (for example  $j$ th) one by one and obtain the Score test statistics. Hence, in this condition, the GEE-UminP test is equivalent to the usual UminP test that combines multiple single-SNP based longitudinal association test statistics.

### *A new class of tests and a data-adaptive test in longitudinal data settings*

Before I introduce the proposed new test method, let me explain the logic in current GEE and Score test based methods.

$$T_{Sum} = 1'U = \sum_{j=1}^p U_j, \quad T_{SSU} = U'U = \sum_{j=1}^p U_j^2,$$

These two tests are called Sum test and SSU test [Pan, 2009] respectively. The former is closely related to other burden tests such like those in [Morgenthaler and Thilly, 2007, Li and Leal, 2008, Madsen and Browning, 2009]. If there is a common association either in direction or strength for causal SNVs with no or few non-associated SNVs, then Sum test and the likes will be most powerful; otherwise, the SSU test and its closely relatives, such as kernel machine regression (KMR or SKAT) [Lee et al., 2012a, Ionita-Laza et al., 2013, Oualkacha et al., 2013, Lee et al., 2012b, Wu et al., 2011] and C-alpha test [Neale et al., 2011], will be most powerful.

Sum test and SSU test are all based on score vector. A more general form of score-based statistic can be generalized as:

$$T_w = W'U = \sum_{j=1}^p W_j U_j$$

where  $W = (W_1, \dots, W_p)'$  is a vector of weights for the  $p$  SNVs [Lin and Tang, 2011]. Different researchers proposed different weighting schemes to pool the information of all SNVs in a region of interest, such as those used in [Madsen and Browning, 2009, Sul et al., 2011, Pan and Shen, 2011, Han and Pan, 2010, Li and Leal, 2008, Zhang et al., 2011, Lin and Tang, 2011, Basu and Pan, 2011]. However, all of these weighting schema have used fixed weights, for example, their weights were chosen to be proportional to the MAFs of SNPs, to the standard deviations of SNPs, to the regression coefficients, or to the single SNP p-value. There is no uniformly best weighting scheme as discussed in [Pan et al., 2014, Basu and Pan, 2011, Pan and Shen, 2011].

As a complement to SNPs weighted average, SNPs selection is preferred in the case that there are many non-associated SNPs among the group of SNPs to be tested. Such methods include aSum+ and aSSU which are based on Neyman-type tests [Neyman, 1937]. However, variable selection will also omit those variables with mild to moderate information. In our context, due to extremely low MAF of RVs, even underlying fact is that the individual RV is strongly associated with trait, there is only limited information stored in this single RV. Dumping seemingly non-informative RVs may actually omit the signals within the group of SNPs. Therefore, we expect the model averaging based tests will outperform the model selection based tests in above settings.

### **The SPU test**

Our goal is to specify a whole class of weights which can cover a wide range of association patterns: for any given data with unknown association pattern, we hope at least one member of the whole class of weights can render a powerful test. We reason that, since association information is largely maintained in the score vector itself as comparable to regression coefficient, score vector is not only the basis in GEE and Score test based methods aforementioned, but may be an informative and simple weight! Specifically, we propose a class of weights

$$W_j = U_{.2,j}^{\gamma-1}$$

for a series of integer value  $\gamma = 1, 2, \dots, \infty$ , leading to the sum of powered score ( $U$ ) tests called SPU tests:

$$T_{SPU(\gamma)} = \sum_{j=1}^p U_{.2,j}^{\gamma-1} U_{.2,j}$$

When  $\gamma = 1$ , the SPU(1) test uses  $\mathbf{1}$  as weight and sums up the information contained in all the SNPs in the region of interest, equivalent to Sum test or burden test; when  $\gamma = 2$ , the SPU(2) test uses  $U$  as weight to itself and is equivalent to SSU test and other variance-component test such as SKAT; when  $\gamma$  keeps increasing, the SPU( $\gamma$ ) test puts higher weights on the  $j$ th SNV with larger  $|U_{.2,j}|$ , while gradually decreasing the weights of other SNVs with smaller  $|U_{.2,j}|$ . As the large value of  $|U_{.2,j}|$  indicates strong association information stored in SNV  $j$  and small value of  $|U_{.2,j}|$  indicates weak or none association information stored in SNV  $j$ , a higher  $\gamma$  tends to put more and more weights on those informative SNVs. When  $\gamma \rightarrow \infty$  as an extreme situation, where  $\infty$  is assumed to be an even number, we have

$$T_{SPU(\gamma)} \propto \|U\|_{\gamma} = \left( \sum_{j=1}^p |U_{.2,j}|^{\gamma} \right)^{\frac{1}{\gamma}} \rightarrow \|U\|_{\infty} = \max_{j=1}^p |U_{.2,j}| \equiv T_{SPU(\infty)}.$$

which takes only the largest element (in absolute value) of score vector. Apparently, SPU( $\infty$ ) is equivalent to UminP test except the variance of each score component is replaced by 1 as in the denominator part.

In our experience, SPU( $\gamma$ ) test with a large  $\gamma > 8$  usually gave similar results as that of SPU( $\infty$ ) test [Pan et al., 2014], thus I will only use  $\gamma \in \Gamma = \{1, 2, \dots, 8, \infty\}$  for the whole dissertation work. Suppose the sample size is large enough or MAF of SNP is large enough, thus the theory that the asymptotic normal distribution of the score vector can hold under the null hypothesis, I will use a simulation based method to calculate the p-value from each  $T_{SPU(\gamma)}$  [Lin, 2005, Seaman and Müller-Myhsok, 2005]. Specifically, suppose  $T$  is a short notation of  $T_{SPU(\gamma)}$  for a specific  $\gamma$  and  $\hat{\Sigma}_{.2}$  is the covariance matrix of the score vector  $U_{.2}$  based on the original data (see Equation 3). We draw B samples of the score vector from its



null distribution:  $U_{.2}^{(b)} \sim MVN(0, \hat{\Sigma}_{.2})$ , with  $b = 1, 2, \dots, B$ , and thus obtain a statistics under null hypothesis:  $T^{(b)} = \sum_{j=1}^p U_{.2,j}^{(b)\gamma}$ . We then can calculate the p-value of  $T_{SPU(\gamma)}$  as  $P_{SPU(\gamma)} = \sum_{b=1}^B \frac{I(T^{(b)} \geq T^{obs}) + 1}{B+1}$ .

### The aSPU test

Given we have a list of  $SPU(\gamma)$  statistics and p-values, we are still not sure which one is the most powerful in a specific data situation. Thus, it will be convenient to have a test which data-adaptively and automatically select/combine the best  $SPU(\gamma)$  test(s). I hereby propose an adaptive SPU (aSPU) test to achieve such a purpose. There is a number of combining methods, such as the exponential combine [Chen et al., 2012], linear combine, quadratic combine and fisher's combine methods [Luo et al., 2010, Peng et al., 2009, Derkach et al., 2013]. In this dissertation work, I will use the minimum-P-value combining method exclusively with room left for other combining methods. For different  $\gamma$ , it is difficult to characterize the power curve of an SPU test in real data situation. Thus, I will use the p-value of a SPU test to approximate its power; this idea has been prevalent in practice. Accordingly, we will have the aSPU test statistic:

$$T_{aSPU} = \min_{\gamma \in \Gamma} P_{SPU(\gamma)},$$

where  $P_{SPU(\gamma)}$  is the p-value of a specific  $SPU(\gamma)$  test.

Similarly as the above simulation based method to obtain p-value of  $T_{SPU(\gamma)}$ , the *same strategy* can be applied to obtain the p-value of  $T_{aSPU}$ . Since the previous simulated  $U_{.2}^{(b)}$  and  $T_{SPU(\gamma)}^{(b)}$  can be reused here, another simulation work becomes *unnecessary*. Specifically, at the SPU test stage we already have the  $U_{.2}^{(b)}$  for  $b = 1, 2, \dots, B$ . We then calculate the corresponding SPU test statistics  $T_{SPU(\gamma)}^{(b)}$  and p-value

$$P_{SPU(\gamma)}^{(b)} = \sum_{b_1 \neq b}^B \frac{I(T_{SPU(\gamma)}^{(b_1)} \geq T_{SPU(\gamma)}^{(b)}) + 1}{(B-1) + 1}$$

for every  $\gamma$  and every  $b$ . Then, we will have  $T_{aSPU}^{(b)} = \min_{\gamma \in \Gamma} P_{SPU(\gamma)}^{(b)}$ , and the final p-value of

aSPU test is:

$$P_{aSPU} = \sum_{b=1}^B \frac{I(T_{aSPU}^{(b)} \leq T_{aSPU}^{obs}) + 1}{B + 1}.$$

It is worth noting again that the same  $B$  simulated score vectors have been used in calculating the  $P_{aSPU}$ .

In practice for genome wide scan purpose, we can use a stage-wise aSPU test strategy: we first start with a smaller  $B$ , for example, use  $B = 1000$  to scan the genomes, then gradually increase  $B$  to, for example,  $10^6$  for a few selected groups of SNPs. For example, we could choose specific genes or windows which passed a pre-determined significance cutoff (for example,  $p\text{-value} \leq 5/B$ ) in the previous stage; we then repeat this process until the pre-determined significance level is reached. For example, a  $p\text{-value}$  of  $\leq 10^{-7}$  requires we increase  $B \geq 10^7$ . In this stage-wise way, we will be able to apply the aSPU test to GWAS data.

## Other versions of aSPU test

- **aSPUw test**

The SPUw test is a *diagonal-variance-weighted* version of the SPU test, defined as:

$$T_{SPUw(\gamma)} = \sum_{j=1}^p \left( \frac{U_{.2,j}}{\sqrt{\hat{\Sigma}_{.2,jj}}} \right)^\gamma$$

Accordingly, **the aSPUw test** statistic is defined as

$$T_{aSPUw} = \min_{\gamma \in \Gamma} P_{SPUw(\gamma)}$$

where  $P_{SPUw(\gamma)}$  is the p-value from  $T_{SPUw(\gamma)}$ . The procedures of getting these values are exactly the same as the above **aSPU** test. Finally, aSPUw p-value can be obtained by:

$$P_{aSPUw} = \sum_{b=1}^B \frac{I(T_{aSPUw}^{(b)} \leq T_{aSPUw}^{obs}) + 1}{B + 1},$$

It is worth noting that **aSPU** and **aSPUw** test can be implemented in the meantime using the same simulated score vector, which makes the computation more efficient.

- **aSPU(w).Score test**

Although the **GEE Score test** will lose power in some scenario of the gene-based GWAS analysis as aforementioned, it still has the unique advantage in some scenarios when the correlation structure among SNPs matters. GEE Score test in the form of  $T = U'_{.2} \Sigma_{.2}^{-1} U_{.2}$  will keep the covariance matrix in the denominator, which preserves the information of possible linkage disequilibrium among SNPs. To combine the strengths from GEE Score test and aSPU(w) test, I propose to adopt the minimum-P-value combining strategy again, yielding the aSPU(w).Score test statistic:

$$T_{aSPU.Score} = \min \left\{ \min_{\gamma \in \Gamma} P_{SPU(\gamma)}, P_{Score} \right\},$$

where  $P_{Score}$  is the p-value of the Score test.

### 5.2.2 Methods for Simulation Settings

I will generate the simulated genotypes following [Wang and Elston, 2007, Pan, 2009, Basu and Pan, 2011]. In brief, I will generate two independent blocks of SNPs for each subject: the first block will included causal SNPs and null SNPs in linkage disequilibrium (LD); the second block will include only null SNPs in LD. I will use the first-order auto-regression (AR(1)) correlation structure to imitate real-world LD among SNPs. I will simulate the longitudinal response variables using AR(1) following [Song et al., 2013]. Then I will take into account the SNPs main effect and time course main effect as fixed effects on the longitudinal response variables **without consideration of SNP  $\times$  time interaction**. I will not consider other covariate effects (such as demographic) in the simulation studies, though they can be simply added without any change to the method. I will refer to several literatures [Pan et al., 2014, Basu and Pan, 2011, Pan and Shen, 2011, Han and Pan, 2010, Pan, 2009]

and the Atherosclerosis Risk in Communities (ARIC) data (<https://www2.csc.unc.edu/aric/>) to set up the simulation parameters, for example,  $\rho_y$  across longitudinal measurements and  $\rho_x$  across SNVs as used in AR(1) correlation structure model.

I did notice that there are other strategies in simulating the genotype data, such as the forward time simulation method to generate population genetic data, which includes coalescence models like two-epoch model and six parameter complex bottleneck model, and allows for simulation of purifying selection effect and scaled fitness effect as well [Boyko et al., 2008, Hernandez, 2008]. Compared with the populational genetics simulation method, my simulation strategy does not take into account the population coalescence theory and assumes each sampled individual genotype is independent to the others. The lack of these properties may be a limit in my simulation studies. However, my simulation strategy takes the edges on the flexible control over the correlation magnitude among SNPs, the desired MAF of SNPs and the proportion of causal SNPs. Such advantages were proved and utilized in developing new association tests in a number of past researches [Wang and Elston, 2007, Pan, 2009, Han and Pan, 2010, Pan and Shen, 2011, Basu and Pan, 2011, Pan et al., 2014, Zhang et al., 2014].

### Methods for simulation of genotype data

To construct a block of SNPs for subject  $i$ , at first, a latent vector  $G_i = (G_{i1}, \dots, G_{ip})'$  will be drawn from a **multivariate normal distribution**  $N(0, R)$ , where  $R$  had a AR(1) correlation structure with its  $(i, j)$ th element in terms of purely correlation  $r_{ij} = \text{Corr}(G_{if}, G_{ig}) = \rho^{|f-g|}$  between any two latent components,  $G_{if}$  and  $G_{ig}$  for  $f \neq g$ . The default  $\rho$  will be set at 0.8 to mimic the real data. Secondly, the latent vector will be dichotomized to yield a haplotype with each latent element  $G_{ij}$  dichotomized to 0 or 1 with probability  $\text{Prob}(G_{ij} = 1) = \text{MAF}$  of  $j$ th SNP; the MAFs will be randomly drawn from a uniform distribution: for causal SNPs, the MAFs will be set between 0.3 and 0.4; for null SNPs, the MAFs will be set between 0.1 and 0.5. Thirdly, we will combine two independent haplotypes to form the genotype  $X_i = (X_{i1}, \dots, X_{ip})'$  for subject  $i$ . The haplotypes for different subject will be gen-

erated **independently**, that is, the subjects will be simulated as perfectly **independent** subjects with no identity by descent (IBD).

Using this strategy, I will placed 35 SNPs in the first block with AR(1) correlation structure to imitate the real LD structure among these SNPs; out of 35 SNPs, I will randomly select 5 SNPs to be causal (that is, they will have non-zero coefficients). To mimic the case in the SNP genotyping array platforms, for example, tag SNPs are genotyped but not the causal SNPs. I will excluded the 5 casual SNPs from the later test procedure. Therefore, in the first block, only null SNPs in LD with these 5 casual SNPs will be retained. I will further place 15 null SNPs in the second block as I planed for the first block. Note that the first block and second block are independent to each other. All the 15 null SNPs from the second block will participate in the test.

### Methods for simulation of phenotype data

To simulate longitudinal quantitative phenotype, I will follow the strategy used in [Song et al., 2013]. Specifically, I will first implement an exploratory analysis, that is the generalized least square estimation with AR(1) correlation structure, on the candidate lipid traits from the ARIC study, to get an approximate estimate of the correlation coefficient between traits across time points. For example, I will obtain  $\rho_{data} = 0.7$  on average for different lipid trait candidates. Secondly, I will setup the mixed effect model to achieve the AR(1) correlation structure as:

$$y_{im} = \mu_i + b_i + \underbrace{\rho e_{i,m-1} + s_{i,m}}_{e_{i,m}}, \quad (5)$$

with  $m = 1, \dots, k$  indexes the longitudinal measurements within subject  $i$  as stated in section 5.2.1;  $\mu_i = Z_i\varphi + X_i\beta = H_i\theta$  as in quantitative trait case (see section 5.2.1);  $b_i$  is the random intercept representing the subject-level random effect, and

$$\rho e_{i,m-1} + s_{i,m} = e_{i,m},$$

where  $\rho$  is lag-one autocorrelation coefficient. I can simply plugin the estimate from the real data here, by setting up  $\rho = 0.7$ .  $e_{i,m}$  is the total residual, which can be divided into two parts: the first part depends on  $e_{i,m-1}$  and the second part is an independent term. I assume the following distribution:

$$\begin{aligned} b_i &\sim N(0, \sigma_b^2) \\ e_{i,m} &\sim N(0, \sigma_e^2) \\ s_{i,m} &\sim N(0, (1 - \rho^2)\sigma_e^2) \end{aligned}$$

It's not difficult to see the term  $\rho e_{i,m-1} + s_{i,m}$ 's variance is equal to the variance of  $e_{i,m}$  by algebraically summing up two parts. Under this assumption, the variance-covariance matrix across longitudinal measurements becomes (assuming  $k = 4$  for the number of longitudinal measurements):

$$\Sigma_{4 \times 4} = Var \begin{pmatrix} b_i + e_{i1} \\ b_i + \rho e_{i1} + s_{i2} \\ b_i + \rho e_{i2} + s_{i3} \\ b_i + \rho e_{i3} + s_{i4} \end{pmatrix} = \sigma_b^2 \begin{pmatrix} 1 & 1 & 1 & 1 \\ 1 & 1 & 1 & 1 \\ 1 & 1 & 1 & 1 \\ 1 & 1 & 1 & 1 \end{pmatrix} + \sigma_e^2 \begin{pmatrix} 1 & \rho & \rho^2 & \rho^3 \\ \rho & 1 & \rho & \rho^2 \\ \rho^2 & \rho & 1 & \rho \\ \rho^3 & \rho^2 & \rho & 1 \end{pmatrix} \quad (6)$$

Among the rightmost two parts summed together in Equation (6), the first part defines the inter-subject variances, and the second part allows the measurements with a  $k$ -interval lag to have a correlation coefficient of  $\rho^k$ . This is closer to reality in some cases for longitudinal data.

### Methods for tuning simulated genetic effect

As noted in association tests, different SNPs contribute to the phenotype with different effect sizes. However, the SNP effect magnitude tuning in the simulation study is not a trivial task. Instead of assigning a  $\beta_d$  coefficient to a SNP with a arbitrary numerical value, for example,

0.1 or 10000, there is a way to use genetic heritability to control the association magnitude from the  $j$ th SNP [Lynch et al., 1998]. Let I first introduce the formula of the variance of the phenotype :

$$Var(y_{im}) = Var(X_{ij})\beta_j^2 + \sigma_{oth}^2 = 2f(1-f)\beta_j^2 + \sigma_{oth}^2 \quad (7)$$

where the Hard-Weinberg equilibrium (HWE) is assumed to hold.  $f$  is the MAF of the SNP;  $\sigma_{oth}^2$  is the residual variance after removing the effect of  $j$ th SNP. Obviously we can see  $\sigma_b^2$  and  $\sigma_e^2$  are contained in  $\sigma_{oth}^2$  (see equation (5)), and if other SNPs' effect are negligible, we expect  $\sigma_b^2 + \sigma_e^2 \approx \sigma_{oth}^2$ . Now let we look at the relationship between genetic heritability (narrow-sense heritability) and equation (7):

$$h^2 = \frac{Var(A)}{Var(P)} \quad (8)$$

This is the classical formula of narrow-sense heritability, with  $Var(A)$  represents the variance due to the additive effects of the alleles, and  $Var(P)$  represents the total variance in the phenotype. In our situation for  $j$ th SNP, this can be expanded to:

$$h_j^2 = \frac{Var_j(A)}{Var(P)} = \frac{Var(X_{ij})\beta_j^2}{Var(y_{im})} = \frac{Var(y_{im}) - \sigma_{oth}^2}{Var(y_{im})} \approx \frac{Var(y_{im}) - \sigma_b^2 - \sigma_e^2}{Var(y_{im})} \quad (9)$$

By systematically solving the equations (7) and (9), we can easily calculate the  $\beta_j$  for  $j$ th SNP once we have pre-determined the value of  $h_j^2$ ,  $\sigma_b^2$ ,  $\sigma_e^2$  and  $f$ . Usually a  $h_j^2$  for a single SNP  $j$  will not be high for complex disease, and we will use  $h_j^2 = 0.001$  as default value in the simulation studies to control  $\beta_j$ .

### 5.2.3 Plan for Simulation Studies

I will evaluate the proposed method's performance using simulated data. Specifically, I will simulate genotype data and longitudinal phenotype data mimicking real data. For example,

the simulated genotype data will allow LD structure among SNPs and the simulated longitudinal trait will allow flexible control over the between-subject variance, the within-subject variance, the number of measurements and the correlation structure among measurements. I will benchmark the new test against several existing methods, such as Sum test, UminP test and Score test. Specifically, I will evaluate whether the Type I error can be controlled at the nominal level (neither inflated nor conservative), and compare the empirical power under different simulation scenarios.

I plan to perform the following simulation studies:

### 1. Power comparison between longitudinal study and cross-sectional study

I will evaluate the power gain from longitudinal study over cross-sectional study by estimating the empirical powers as a function of the number of visits (starting from one, that is actually the cross-sectional study, to  $k$ , for example, four as the maximum measurement number). We will also test the power gain magnitude under different levels of within-subject correlation coefficient.

The quantities of interested include:

- (a) the magnitude of power gain at different levels of  $\rho$ , the within-subject correlation coefficient as used in the simulation of the AR(1) correlation structure. For example,  $\rho = 0.3$  represents a weak correlation between measurements of the same subject, while  $\rho = 0.7$  represents a strong correlation;
- (b) the empirical powers as a function of the number of visits. We want to confirm the magnitude of the power gain coming from each extra follow-up measurement. There may be the case when  $k$  increases to a specific level, for example three, the power gain after it will be negligible as compared to previous power gains. This is the so called “elbow point”, which is quite meaningful in deciding a sufficient point to stop. In our settings, we do not want to infinitely increasing the  $k$ , which will lead to a larger and unnecessary cost. A sufficient  $k$  will achieve a



relatively higher power to meet the study requirement, for example, a power of 0.9 in longitudinal studies, while avoiding unnecessary cost from pursuing an even larger  $k$ .

## 2. Type I error benchmark under the default simulation settings with varying sample sizes

I will evaluate the Type I error of the aSPU test and its extensions (we will call them aSPU family hereinafter) as compared with several existing tests: Score GEE, UminP, Sum Test, weighted Sum Test and SSU test. I will set the significance level at 0.05. I provide a sample table below to show format of the future result presentation (dummy numbers shown in each cell).

n	Score	UminP	SumP	SumP.w	SSU	aSPU	aSPUw	aSPU.sco	aSPUw.sco
500	0.038	0.059	0.048	0.033	0.034	0.052	0.045	0.040	0.058
1000	0.048	0.054	0.049	0.059	0.045	0.035	0.044	0.049	0.047
2000	0.056	0.042	0.043	0.033	0.049	0.062	0.045	0.048	0.048
3000	0.055	0.053	0.067	0.050	0.055	0.033	0.054	0.046	0.049

Table 1: Sample Table of Type I error Benchmark among tests

## 3. Empirical power benchmark under the default simulation settings with varying sample sizes

I will benchmark the empirical power among aSPU family tests and several existing tests. I will keep the significance level  $\alpha$  at 0.05, and evaluate the empirical power for sample size  $n$  equal to 500, 1000, 2000 and 3000. We will present either a figure plotting power curve as a function of  $n$  for each participating test or a power table in the similar format as the empirical Type I error table above.

**4. Empirical power benchmark under the simulation settings where half of casual SNPs are in the opposite effect direction**

Out of the 5 causal SNPs (simulated in the region with all other SNPs but excluded from the tests assuming that the causal SNPs are not genotyped), I will set 2 of them to have opposite effect direction compared with the rest 3 SNPs by flipping the signs of SNP main effects. Other settings will remain the same as above. I will keep the significance level  $\alpha$  at 0.05, and evaluate the empirical power for sample size  $n$  equal to 500, 1000, 2000 and 3000. I will present either a figure plotting power curve as a function of  $n$  for each test under consideration or a power table in the similar format as the empirical Type I error table above.

**5. Empirical power benchmark under the simulation settings where the number of null SNPs number grows**

In association testing, there is sometimes the case that in a region of interest, casual SNP signals are very sparse. Namely, there exists many null SNPs. I hence want to investigate the performance of the aSPU family tests in the presence of a larger proportion of null SNPs in the region. I will gradually increase the number of null SNPs from 50 to 75, 100, 200, and then finally 400. I will only consider  $n = 3000$  as the sample size in this scenario. I will keep all other settings the same as Scenario 3 (the default simulation settings) above. I will present either a figure plotting power curve as a function of number of null SNPs for each test under consideration or a power table in the similar format as the empirical Type I error table above.

**6. Empirical power benchmark under the simulation settings where working correlation structure varies**

I will investigate the aSPU family tests' performance under other working correlation structures than the working independence, such as AR(1), compound symmetry, and unstructured. Note that, as I simulated the longitudinal trait using the AR(1) cor-

relation structure as described in Section 5.2.2, fitting GEE with the AR(1) working correlation matrix is actually using the true correlation matrix. I will keep all other settings the same as Scenario 3 (the default simulation settings) above. I will present either a figure plotting power curve as a function of  $n$  for each test under comparison under a specific working correlation matrix or a power table in the similar format as the empirical Type I error table above. It is of interest to investigate the effect of combining a specific working correlation matrix and a specific  $n$  for each test.

### **5.3 Methods for Aim 1(b): To develop data-adaptive SNP-set based association tests for longitudinal data analysis within the Generalized Estimating Equations (GEE) framework for rare variants**

#### **5.3.1 Statistical Modeling**

In the previous section 5.2.1, I have discussed the method development of the aSPU family tests on common variants with a longitudinal trait. In this section, I will discuss the extension of the proposed methods to rare variants.

While MAF of RVs are usually low, for example, between 0.001 to 0.01, the property of asymptotically normal distribution of either the regression coefficient or score vector may not hold. The simulation-based p-value calculating method as proposed in Aim 1(a) for CVs may not be sufficient for RV analysis. Specifically, in last section, we have:

$$U_{.2}^{(b)} \sim MVN\left(0, \hat{\Sigma}_{.2}\right)$$

with  $b = 1, 2, \dots, B$ , and thus obtain a statistics under null hypothesis:  $T^{(b)} = \sum_{j=1}^p U_{.2,j}^{(b)\gamma}$ .

We then calculate the p-value of  $T_{SPU(\gamma)}$  as  $P_{SPU(\gamma)} = \sum_{b=1}^B \frac{I(T^{(b)} \geq T^{obs}) + 1}{B+1}$ .

The above algorithms will hold in the RV case by large, except that the  $U_{.2}^{(b)}$  may not follow the multivariate normal distribution any longer. As a remedy, I propose a permutation based method to generate the empirical null distribution of  $U_{.2}^{(b)}$  instead of the previous simulation based method. The permutation strategy will maintain the relationship between longitudinal traits and possible covariates such as age and gender for subject  $i$ , in other words, the permutation strategy will only permute the genotype part in the regression model. The algorithm will be also robust to missing data as this is usually the case in longitudinal data settings. After we obtain enough  $U_{.2}^{*(b)}$  from permutation strategy to form an empirical null distribution, the left work of the aSPU tests for RVs will be exactly the same as we did on CVs. This is because, the only difference between the CV analysis and RV analysis is, the null distribution of score vectors for CVs is obtained by simulation based method, while for RVs, the null distribution of score vectors is obtained by permutation based method.

### 5.3.2 Methods for Simulation Settings

The simulation strategy of RV genotype data is almost the same as previous strategy for generating CV genotype data (see section 5.2.2), except that:

1. the MAF of RVs, regardless of casual one or null one, are set between 0.001 and 0.01.
2. the casual RVs are not excluded from later test stage as we expect the whole-genome sequencing or exome sequencing platform will identify high density variants including the casual ones.

We will use the same simulated longitudinal phenotype data as for CVs.

### 5.3.3 Plan for Simulation Studies

I will test the proposed methods' performance using simulated data. Specifically, we will simulate RV genotype data and longitudinal phenotype data mimicking real data. For example,

the simulated genotype data will allow LD structure among SNPs and the simulated longitudinal trait will allow flexible control over the between-subject variance, the within-subject variance, the number of measurements and the correlation structure among measurements. I will benchmark the new test against several existing methods, such as Sum test, UminP test and Score test. Specifically, I will evaluate whether the Type I error could be controlled at the nominal level (neither inflated nor conservative), and compare the empirical power under different simulation scenarios. I will evaluate, on simulation data, the effect of implementing permutation or parametric bootstrap strategy. We expect to see such procedures can provide a better control of type I error and a more unbiased estimate of the real power.

I plan to perform the following simulation studies:

**1. Type I error benchmark using simulation-based P-value calculating method under the default settings with varying sample sizes**

Similarly as I planned for CVs in Aim 1(a), I will evaluate the aSPU family tests' Type I error performance as compared to a few existing tests for RVs. I will still use the simulation-based P-value calculating method as we planned for CVs before. I will compare the aSPU family tests with SSU, SSUw, Score, Sum, UminP (calculated by simulation-based method) and mvn.UminP (calculated by approximating a multivariate normal distribution) test. I will set the significance level  $\alpha$  at 0.05. I provide a sample table below to show the format of future presentation (dummy numbers shown in each cell).

n	pSSU	pSSUw	pScore	pSum	mvn.UminP	UminP	SPU(1)	SPUw(1)	SPU(2)	SPUw(2)	aSPU	aSPUw	aSPU.sco	aSPUw.sco
500	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.021	0.055	0.035
1000	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055
2000	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.066	0.062	0.062	0.062
3000	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055	0.055

Table 2: Sample Table of Type I error Benchmark among tests using simulation-based method in RV analysis. mvn.UminP: UminP calculated by approximating a MVN distribution; UminP: UminP method calculated by simulation-based method.

**2. Empirical power benchmark using simulation-based P-value calculating method**

**under the default settings with varying sample sizes**

I will benchmark the empirical power among aSPU family tests and several existing tests in RV analysis using simulation-based P-value calculating method. I will keep the significance level  $\alpha$  at 0.05, and evaluate the empirical power for sample size  $n$  equal to 500, 1000, 2000 and 3000. I will present either a figure plotting power curve as a function of  $n$  for each test considered or a power table in the similar format as the empirical Type I error table above.

**3. Type I error benchmark using permutation-based P-value calculating method under the default settings with varying sample sizes**

I plan to compare the result from previous Scenario 1 to the Type I error benchmark result from using **permutation-based** P-value calculating method. I will compare the aSPU family tests with SSU, SSUw, Score, Sum, UminP (calculated by simulation-based method) and mvn.UminP (calculated by approximating a multivariate normal distribution) tests. I will set the significance level  $\alpha$  at 0.05. I will present the result using a similar table as the previous example table 2.

**4. Empirical power benchmark using permutation-based P-value calculating method under the default settings with varying sample sizes**

I will benchmark the empirical power among aSPU family tests and several existing tests in RV analysis using **permutation-based** P-value calculating method. I will also compare them to the one computed by **simulation-based** P-value calculating method in Scenario 2. I will discuss the observed difference between these two methods for RV analysis. I will keep the significance level  $\alpha$  at 0.05, and evaluate the empirical power for sample size  $n$  equal to 500, 1000, 2000 and 3000. I will present either a figure plotting power curve as a function of  $n$  for each test under comparison or a power table in the similar format as the previous example table 2.

**5. Evaluation of the performance of proposed aSPU.aSPUw.Score test**

Within the aSPU, aSPUw, and Score test, there may be at least one test having a high power in a specific data scenario, depending on the association pattern and the correlation structure within SNPs. I plan to combine the three tests to the aSPU.aSPUw.Score test.

$$T_{aSPU.aSPUw.Score} = \min \left\{ \min_{\gamma \in \Gamma} P_{SPU(\gamma)}, \min_{\gamma \in \Gamma} P_{SPUw(\gamma)}, P_{Score} \right\},$$

Afterwards, I will evaluate the performance of the proposed test with regard to empirical Type I error and power. We are interested in whether the proposed new test, that have combined advantages from two adaptive tests and the score test, can control the Type I error well and maintain a higher power in all scenarios (regardless of the variance homogeneity of RVs). I will present the result using a similar table or power curve plot as above.

## 5.4 Methods for Aim 2: To develop the pathway-based data-adaptive association tests for longitudinal data analysis

In the previous sections, I have discussed the method development of the aSPU family tests in a gene-based or region-based manner for CVs and RVs. Here, I will discuss the extension of the new methods to the pathway-based manner, the so called **Path-aSPU**. Path-aSPU is proposed mainly for analyzing RVs. Since RVs have extreme low MAFs, they need more aggregation to increase the test power. Like we aggregate the RVs in a gene, we further aggregate the genes in a pathway. Additionally, there may be a large number of non-associated RVs, a preferred case for the aSPU family. Thus I expect Path-aSPU will perform well when comparing to existing methods, such as SSU, Sum and UminP test.

### 5.4.1 Statistical Modeling

A pathway analysis will involve multiple genes (for example, 20 or 50). Too few or too many genes in a pathway will make the pathway difficult to interpret in the biological perspective. For example, a pathway with only two genes and another pathway with 2000 genes are both difficult to interpret. Therefore, I will consider the pathway with a reasonable number of genes, for example, 20 to 200. For each gene within a pathway, it may contain different numbers of RVs. For example, a gene has 10 RVs while another gene has 400 RVs. This bring over a new problem that a larger gene (a gene with more RVs) may dominate a smaller gene (a gene with fewer RVs). Hereby, I propose to modify the aSPU test to adjust for various gene length, thus avoid the dominant influence from a large (or small) gene.

Let the short notation  $U_g$  represent  $U_{.2}$  for genotype data, and  $U_g = (U_{g,1}, U_{g,1}, \dots, U_{g,p_g})'$  represent the score vector for gene  $g$  with  $p_g$  RVs from the GEE fitting. Given a pathway (or a gene set)  $S$ , the gene-specific SPU statistic is as follows:

$$T_{SPU(\gamma;g)} \propto ||U_g.||_\gamma = \left( \frac{\sum_{j=1}^{p_g} |U_{g,j}|^\gamma}{p_g} \right)^{\frac{1}{\gamma}} \quad (10)$$

Then accordingly, the pathway-based SPU statistic is

$$T_{Path-SPU(\gamma,\gamma 2;S)} = \sum_{g \in S} (T_{SPU(\gamma;g)})^{\gamma 2} \quad (11)$$

Note the  $T_{SPU(\gamma;g)}$  is now standardized by the gene-specific number of RVs,  $p_g$ ; for a given gene  $g$ ,  $T_{SPU(\gamma;g)}$  is equivalent to previous notation  $T_{SPU(\gamma)}$  by large. Again, for any given  $(\gamma, \gamma 2)$ , I will recourse to the same simulation or permutation based strategy to calculate the p-value  $P_{Path-SPU(\gamma,\gamma 2;S)}$  from  $T_{Path-SPU(\gamma,\gamma 2;S)}$ . Then we will have the **pathway-based aSPU** test statistic:

$$T_{Path-aSPU(S)} = \min_{\gamma,\gamma 2} P_{Path-SPU(\gamma,\gamma 2;S)} \quad (12)$$



We again adopt the same strategy as previous, that is we will utilize the same set of simulated  $U$  generated in the previous step for calculating  $P_{Path-SPU(\gamma, \gamma_2; S)}$  to calculate the final **pathway-based aSPU** p-value  $P_{Path-aSPU(S)}$ .

The intuition of  $\gamma_2$  is like that of  $\gamma$ : If we treat the pathway as the gene and the gene as the RVs. A larger  $\gamma_2$  ( $\gamma$ ) put more weights on heavily associated genes (RVs), when gradually ignoring the less associated genes (RVs) in a pathway (gene). An extreme case is  $\gamma_2 = \infty$ , as I already explained  $\gamma = \infty$ 's interpretation in section 5.2.1, it indicates the pathway-based analysis actually used only one gene - the most heavily associated gene with the trait. Since the goal of pathway-based analysis is to take advantage of multiple “co-working” genes, and aggregate more RVs, it is less meaningful to consider the use of a  $\gamma_2 = \infty$ . Instead, I propose to use  $\gamma_2 \in \Gamma_2 = \{1, 2, 4, 8\}$ . The reason is that, at the pathway level, the statistic  $T_{SPU(\gamma; g)}$  is always a positive number, not like that  $U_{2,j}$  from the GEE model fitting for variants can have different signs (SNP effect directions). Thus, deliberately assigning both odd and even number of  $\gamma_2$  becomes unnecessary, and I can actually use most representative  $\gamma_2$  values and expect them to have most distinct effects from each other. Fewer  $\gamma_2$  candidates will also expedite the computation. To these purposes,  $\gamma_2 \in \Gamma_2 = \{1, 2, 4, 8\}$  will cover Sum-like test, SSU-like test, and two more tests preferring the sparse-casual-gene situation (for example, only 2 or 3 genes are associated with the longitudinal trait in a pathway with 20 genes).

#### 5.4.2 Methods for Simulation Settings

The simulation strategy of RVs within a gene is the the same as section 5.3.2. I will use the same simulated longitudinal phenotype data as in Aim 1(a).

With regard to the pathway consisting of multiple genes, I will simulate a pathway with 20 genes. Each gene  $g$  will contain  $p_g$  RVs with  $p_g$  randomly draw from a uniform distribution  $U(5, 20)$ . 5 of the 20 genes will be randomly selected to be causal, with each casual gene containing  $U(1, 3)$  causal RVs.

### 5.4.3 Plan for Simulation Studies

I will test the Path-aSPU tests' performance on the simulated data to evaluate the empirical Type I error and power, with comparison to several existing tests like SSU, Sum, Score and UminP test. I will fix the sample size  $n = 1000$ ; I will set the single SNP heritability  $h_j^2 \in \{0.001, 0.0025, 0.005, 0.0075, 0.01\}$  to control the effect size. All other settings will be the same as Scenario 2 of Aim 1(a) simulation study plan (see section 5.2.3).

Optionally, I may consider more extensive simulation studies, such as tuning the casual RV number within a casual gene or tuning the number of casual genes within a pathway, using independent RVs within a gene instead of correlated RVs in AR(1), and using different working correlation matrix. In these ways, I can evaluate the robustness of the Path-aSPU performance.

## 5.5 Methods for Aim 3: To develop the software package for method implementation

I will develop a software package using R language and Linux shell script mainly. The package/software will require a few existing R packages, such as “data.table” enables big data manipulation and “geepack” enables GEE estimation, to make itself functional and more efficient. All dependent R packages can be freely downloaded from CRAN (<http://cran.r-project.org/>). The software package will install the dependent R packages automatically upon first time software installation/setup.

The software package will have a list of nice properties. It will be straightforward to install and use for 1st-time user. The software package will allow user to run the program in a very flexible parallel computation framework. For example, user can choose to use a single node with multiple cores or use multiple nodes with multiple cores. I will employ either SOCKET or MPI as the parallel computing protocol. I will use R packages “SNOW”, “doSNOW” and

“doMC” to fulfill the parallel function. The software package will also have the state-of-the-arts technique to enable efficient implementation of the aSPU methods, such as the hash table, radix sort, memory-efficient task send and collect among nodes, and calling C++ code for some intensive loops.

The software package will finally have a clear help document with demonstration examples in addition to on-screen help brief (triggered by command, for example, “Executable.r -h”). The software can be operated through Linux command line arguments. For example, the command line that “Executable.r -i inputname -o outputname -p FALSE -S SNOW -m FALSE”, will use the executable file “Executable.r” to process the input file “inputname” and later output the file “outputname”. It disables the permutation-based method, instead uses the simulation-based method by specifying “-p FALSE”. It uses parallel computing schema set by “SNOW” and executes on single node with multiple cores as indicated by “-m FALSE”. This is a short example, the real arguments could be more complicated to allow more flexible control of the software package.

I will test our software package on the simulated dataset for the purpose of debugging and optimization. Since we know the “real answer” for simulated dataset, testing the software package on such dataset and evaluate the result can help us confirm the scientific function of the software package is correct.

I will test our software package on the ARIC data for the purpose of debugging and optimization. I expect the real dataset can give us more useful feedback from, for example, the innate data complexity, which simulated dataset usually lack, to help us improve the robustness, convenience and efficiency of the software package.

## **5.6 Methods for Real Data Application for Proposed Aims**

Here I will summarize the methods of real data application for proposed Aims 1 and 2. For Aim 3, since it is for software package development, I will use the package, test it, and improve

its performance and robustness through the whole real data application processes for Aim 1 and 2. As shared in common, I will apply the developed novel methods for both Aims 1 and 2 to the Atherosclerosis Risk in Communities (ARIC) data (<https://www2.csc.unc.edu/aric/>). I will exclusively use the Caucasian samples ( $n = 11478$ ). Specifically, I will select one or several traits from ARIC cohort data as the response variable(s) with longitudinal measurements. Candidate traits include four cardiovascular disease-related lipid traits, which are total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TRG). I will **take cautions before using these lipid traits**, such as accounting for lipid-lowering therapy in TC and LDL-C traits, and natural log transformation on the TRG trait according to the procedures described in [Peloso et al., 2014].

For genotype data part, in Aim 1(a), I will use the common variants genotyped by the ExomeChip [Grove et al., 2013] platform in the ARIC study. I will follow conventional quality control (QC) criteria for GWAS. For example, the MAF of any SNP should be greater than 5%, missing rate of both single SNP and single subject should be less than 5% and hardy-weinberg-equilibrium (HWE) test p-value should be greater than 0.001. In Aim 1(b), I will use the rare variants genotyped by the same ExomeChip platform in the ARIC study. I will follow conventional QC criteria for rare variants analysis. For example, the MAF of any SNP should be less than 5%, missing rate of both single SNP and single subject should be less than 5%, HWE test p-value should be greater than 0.001 and region aggregate counts of minor alleles should be greater than 20 or 40 as previously done in [Lange et al., 2014, Peloso et al., 2014]. In Aim 2, I will define the gene pathway by public pathway resources like KEGG [Ogata et al., 1999] and BioCarta [Nishimura, 2001]. I will consider the medium size pathways in selected database, for example, the pathway with 20 to 100 genes. I will use the rare variants from the ExomeChip platform [Grove et al., 2013] in the ARIC study. I will adopt the same QC criteria for rare variant analysis as in Aim 1(b).

With regard to covariates, I will include top two principal components eigenvectors (PCs) produced by EIGENSTRAT [Price et al., 2006] in the longitudinal regression model to adjust for the potential population structure within the ARIC Caucasian subjects. Additionally, I will include subject's demographic information such as age, gender and BMI. I will also include the fixed time course effect as a covariate.

I will run gene-based test with gene boundary defined by ANNOVAR [Wang et al., 2010b], a software package providing functional annotation of genetic variants from high-throughput sequencing data or array data. Optionally, if sliding-window based test is chosen for Aim 1(a), I will set the window size to 40 consecutive SNPs in a window, while neighboring windows share 10 SNPs as the step size so that SNPs signals in the gap between two windows would not be omitted.

By implementing the real data application, I expect to verify known risk genes and/or pathways related to either cardiovascular disease or associated trait level, therefore I can validate the functionality of our proposed methods. I also look forward to identify the novel risk genes and/or pathways, which will provide new valuable information to the disease research consortium. Since I will provide a software package to implement our new methods, I will test its correctness and robustness through the whole real data application.

## References

- [Ansorge, 2009] Ansorge, W. J. (2009). Next-generation dna sequencing techniques. *New biotechnology*, 25(4):195–203.
- [Ashburner et al., 2000] Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000). Gene ontology: tool for the unification of biology. *Nature genetics*, 25(1):25–29.
- [Association et al., 2014] Association, A. et al. (2014). 2014 alzheimer’s disease facts and figures. *Alzheimer’s & Dementia*, 10(2):e47–e92.
- [Aulchenko et al., 2009] Aulchenko, Y. S., Ripatti, S., Lindqvist, I., Boomsma, D., Heid, I. M., Pramstaller, P. P., Penninx, B. W. J. H., Janssens, A. C. J. W., Wilson, J. F., Spector, T., Martin, N. G., Pedersen, N. L., Kyvik, K. O., Kaprio, J., Hofman, A., Freimer, N. B., Jarvelin, M.-R., Gyllenstein, U., Campbell, H., Rudan, I., Johansson, A., Marroni, F., Hayward, C., Vitart, V., Jonasson, I., Pattaro, C., Wright, A., Hastie, N., Pichler, I., Hicks, A. A., Falchi, M., Willemsen, G., Hottenga, J.-J., de Geus, E. J. C., Montgomery, G. W., Whitfield, J., Magnusson, P., Saharinen, J., Perola, M., Silander, K., Isaacs, A., Sijbrands, E. J. G., Uitterlinden, A. G., Witteman, J. C. M., Oostra, B. A., Elliott, P., Ruukonen, A., Sabatti, C., Gieger, C., Meitinger, T., Kronenberg, F., Döring, A., Wichmann, H.-E., Smit, J. H., McCarthy, M. I., van Duijn, C. M., Peltonen, L., and , E. N. G. A. G. E. C. (2009). Loci influencing lipid levels and coronary heart disease risk in 16 european population cohorts. *Nat Genet*, 41(1):47–55.
- [Bansal et al., 2010] Bansal, V., Libiger, O., Torkamani, A., and Schork, N. J. (2010). Statistical analysis strategies for association studies involving rare variants. *Nat Rev Genet*, 11(11):773–785.
- [Basu and Pan, 2011] Basu, S. and Pan, W. (2011). Comparison of statistical tests for disease association with rare variants. *Genet Epidemiol*, 35(7):606–619.

- [Belsky et al., 2013] Belsky, D. W., Moffitt, T. E., Baker, T. B., Biddle, A. K., Evans, J. P., Harrington, H., Houts, R., Meier, M., Sugden, K., Williams, B., et al. (2013). Polygenic risk and the developmental progression to heavy, persistent smoking and nicotine dependence: evidence from a 4-decade longitudinal study. *JAMA psychiatry*, 70(5):534–542.
- [Benros et al., 2014] Benros, M. E., Nielsen, P. R., Nordentoft, M., Eaton, W. W., Dalton, S. O., and Mortensen, P. B. (2014). Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study.
- [Bhatia et al., 2010] Bhatia, G., Bansal, V., Harismendy, O., Schork, N. J., Topol, E. J., Frazer, K., and Bafna, V. (2010). A covering method for detecting genetic associations between rare variants and common phenotypes. *PLoS computational biology*, 6(10):e1000954.
- [Boyko et al., 2008] Boyko, A. R., Williamson, S. H., Indap, A. R., Degenhardt, J. D., Hernandez, R. D., Lohmueller, K. E., Adams, M. D., Schmidt, S., Sninsky, J. J., Sunyaev, S. R., et al. (2008). Assessing the evolutionary impact of amino acid mutations in the human genome. *PLoS genetics*, 4(5):e1000083.
- [Cai et al., 2012] Cai, T., Lin, X., and Carroll, R. J. (2012). Identifying genetic marker sets associated with phenotypes via an efficient adaptive score test. *Biostatistics*, 13(4):776–790.
- [Cantor et al., 2010] Cantor, R. M., Lange, K., and Sinsheimer, J. S. (2010). Prioritizing gwas results: a review of statistical methods and recommendations for their application. *The American Journal of Human Genetics*, 86(1):6–22.
- [Capanu et al., 2011] Capanu, M., Concannon, P., Haile, R. W., Bernstein, L., Malone, K. E., Lynch, C. F., Liang, X., Teraoka, S. N., Diep, A. T., Thomas, D. C., Bernstein, J. L., , W. E. C. A. R. E. S. C. G., and Begg, C. B. (2011). Assessment of rare brca1

- and *brca2* variants of unknown significance using hierarchical modeling. *Genet Epidemiol*, 35(5):389–397.
- [Caspi et al., 2008] Caspi, R., Foerster, H., Fulcher, C. A., Kaipa, P., Krummenacker, M., Latendresse, M., Paley, S., Rhee, S. Y., Shearer, A. G., Tissier, C., et al. (2008). The metacyc database of metabolic pathways and enzymes and the biocyc collection of pathway/genome databases. *Nucleic acids research*, 36(suppl 1):D623–D631.
- [Chai et al., 2009] Chai, H.-S., Sicotte, H., Bailey, K. R., Turner, S. T., Asmann, Y. W., and Kocher, J.-P. A. (2009). Glossi: a method to assess the association of genetic loci-sets with complex diseases. *BMC bioinformatics*, 10(1):102.
- [Chen et al., 2009] Chen, L., Zhang, L., Zhao, Y., Xu, L., Shang, Y., Wang, Q., Li, W., Wang, H., and Li, X. (2009). Prioritizing risk pathways: a novel association approach to searching for disease pathways fusing snps and pathways. *Bioinformatics*, 25(2):237–242.
- [Chen et al., 2012] Chen, L. S., Hsu, L., Gamazon, E. R., Cox, N. J., and Nicolae, D. L. (2012). An exponential combination procedure for set-based association tests in sequencing studies. *The American Journal of Human Genetics*, 91(6):977–986.
- [Chen et al., 2010a] Chen, L. S., Hutter, C. M., Potter, J. D., Liu, Y., Prentice, R. L., Peters, U., and Hsu, L. (2010a). Insights into colon cancer etiology via a regularized approach to gene set analysis of gwas data. *The American Journal of Human Genetics*, 86(6):860–871.
- [Chen et al., 2010b] Chen, X., Wang, L., Hu, B., Guo, M., Barnard, J., and Zhu, X. (2010b). Pathway-based analysis for genome-wide association studies using supervised principal components. *Genetic epidemiology*, 34(7):716–724.
- [Cheng et al., 1999] Cheng, S., Grow, M. A., Pallaud, C., Klitz, W., Erlich, H. A., Visvikis, S., Chen, J. J., Pullinger, C. R., Malloy, M. J., Siest, G., et al. (1999). A multilocus genotyping assay for candidate markers of cardiovascular disease risk. *Genome research*, 9(10):936–949.



- [Cortes and Brown, 2011] Cortes, A. and Brown, M. A. (2011). Promise and pitfalls of the immunochip. *Arthritis Res Ther*, 13(1):101.
- [Cox and Snell, 1989] Cox, D. R. and Snell, E. J. (1989). *Analysis of binary data*, volume 32. CRC Press.
- [Craig et al., 2008] Craig, J. et al. (2008). Complex diseases: Research and applications. *Nature Education*, 1(1):184.
- [De la Cruz et al., 2010] De la Cruz, O., Wen, X., Ke, B., Song, M., and Nicolae, D. L. (2010). Gene, region and pathway level analyses in whole-genome studies. *Genet Epidemiol*, 34(3):222–231.
- [Dennis Jr et al., 2003] Dennis Jr, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., Lempicki, R. A., et al. (2003). David: database for annotation, visualization, and integrated discovery. *Genome biol*, 4(5):P3.
- [Derkach et al., 2013] Derkach, A., Lawless, J. F., and Sun, L. (2013). Robust and powerful tests for rare variants using fisher’s method to combine evidence of association from two or more complementary tests. *Genetic epidemiology*, 37(1):110–121.
- [Diggle et al., 2002] Diggle, P., Heagerty, P., Liang, K.-Y., and Zeger, S. (2002). *Analysis of longitudinal data*. Oxford University Press.
- [Eichler et al., 2010] Eichler, E. E., Flint, J., Gibson, G., Kong, A., Leal, S. M., Moore, J. H., and Nadeau, J. H. (2010). Missing heritability and strategies for finding the underlying causes of complex disease. *Nature Reviews Genetics*, 11(6):446–450.
- [Fan et al., 2013] Fan, R., Wang, Y., Mills, J. L., Wilson, A. F., Bailey-Wilson, J. E., and Xiong, M. (2013). Functional linear models for association analysis of quantitative traits. *Genetic epidemiology*, 37(7):726–742.

- [Feng et al., 2011] Feng, T., Elston, R. C., and Zhu, X. (2011). Detecting rare and common variants for complex traits: sibpair and odds ratio weighted sum statistics (spwss, orwss). *Genetic epidemiology*, 35(5):398–409.
- [for Blood Pressure Genome-Wide Association Studies et al., 2011] for Blood Pressure Genome-Wide Association Studies, I. C. et al. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*, 478(7367):103–109.
- [Fridley and Biernacka, 2011] Fridley, B. L. and Biernacka, J. M. (2011). Gene set analysis of snp data: benefits, challenges, and future directions. *European Journal of Human Genetics*, 19(8):837–843.
- [Fridley et al., 2010] Fridley, B. L., Jenkins, G. D., and Biernacka, J. M. (2010). Self-contained gene-set analysis of expression data: an evaluation of existing and novel methods. *PLoS One*, 5(9).
- [Fu et al., 2013] Fu, W., O’Connor, T. D., Jun, G., Kang, H. M., Abecasis, G., Leal, S. M., Gabriel, S., Rieder, M. J., Altshuler, D., Shendure, J., Nickerson, D. A., Bamshad, M. J., , N. H. L. B. I. E. S. P., and Akey, J. M. (2013). Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature*, 493(7431):216–220.
- [Furlotte et al., 2012] Furlotte, N. A., Eskin, E., and Eyheramendy, S. (2012). Genome-wide association mapping with longitudinal data. *Genetic epidemiology*, 36(5):463–471.
- [Go et al., 2013] Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., SHIFAN, D., Ford, E. S., Fox, C. S., et al. (2013). Executive summary: Heart disease and stroke statistics: 2013 update: A report from the american heart association. *Circulation*, 127(1):143–146.
- [Goeman and Bühlmann, 2007] Goeman, J. J. and Bühlmann, P. (2007). Analyzing gene expression data in terms of gene sets: methodological issues. *Bioinformatics*, 23(8):980–987.

- [Gough, 2002] Gough, N. R. (2002). Science’s signal transduction knowledge environment. *Annals of the New York Academy of Sciences*, 971(1):585–587.
- [Grove et al., 2013] Grove, M. L., Yu, B., Cochran, B. J., Haritunians, T., Bis, J. C., Taylor, K. D., Hansen, M., Borecki, I. B., Cupples, L. A., Fornage, M., et al. (2013). Best practices and joint calling of the humanexome beadchip: the charge consortium. *PLoS One*, 8(7):e68095.
- [Guo et al., 2005] Guo, X., Pan, W., Connett, J. E., Hannan, P. J., and French, S. A. (2005). Small-sample performance of the robust score test and its modifications in generalized estimating equations. *Statistics in medicine*, 24(22):3479–3495.
- [Han and Pan, 2010] Han, F. and Pan, W. (2010). A data-adaptive sum test for disease association with multiple common or rare variants. *Human heredity*, 70(1):42–54.
- [Heiss, 1989] Heiss, G. (1989). Atherosclerosis risk in communities: a follow-up study of early arterial lesions in the general population. *Pathology of Human Atherosclerotic Plaque*. New York, NY: Springer-Verlag, 877:888.
- [Hernandez, 2008] Hernandez, R. D. (2008). A flexible forward simulator for populations subject to selection and demography. *Bioinformatics*, 24(23):2786–2787.
- [Hindorff et al., 2009] Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S., and Manolio, T. A. (2009). Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proceedings of the National Academy of Sciences*, 106(23):9362–9367.
- [Hirschhorn, 2009] Hirschhorn, J. N. (2009). Genomewide association studies—illuminating biologic pathways. *New England Journal of Medicine*, 360(17):1699.

- [Hirschhorn and Daly, 2005] Hirschhorn, J. N. and Daly, M. J. (2005). Genome-wide association studies for common diseases and complex traits. *Nature Reviews Genetics*, 6(2):95–108.
- [Hoffmann et al., 2010] Hoffmann, T. J., Marini, N. J., and Witte, J. S. (2010). Comprehensive approach to analyzing rare genetic variants. *PLoS One*, 5(11):e13584.
- [Holden et al., 2008] Holden, M., Deng, S., Wojnowski, L., and Kulle, B. (2008). Gsea-snp: applying gene set enrichment analysis to snp data from genome-wide association studies. *Bioinformatics*, 24(23):2784–2785.
- [Holmans et al., 2009] Holmans, P., Green, E. K., Pahwa, J. S., Ferreira, M. A., Purcell, S. M., Sklar, P., Owen, M. J., O’Donovan, M. C., and Craddock, N. (2009). Gene ontology analysis of gwa study data sets provides insights into the biology of bipolar disorder. *The American Journal of Human Genetics*, 85(1):13–24.
- [Hu et al., 2013] Hu, H., Huff, C. D., Moore, B., Flygare, S., Reese, M. G., and Yandell, M. (2013). Vaast 2.0: Improved variant classification and disease-gene identification using a conservation-controlled amino acid substitution matrix. *Genetic epidemiology*, 37(6):622–634.
- [Investigators et al., 1989] Investigators, A. et al. (1989). The atherosclerosis risk in community (aric) study: Design and objectives. *American journal of epidemiology*, 129(4):687–702.
- [Inzucchi et al., 2012] Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., and Matthews, D. R. (2012). Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the american diabetes association (ada) and the european association for the study of diabetes (easd). *Diabetes care*, 35(6):1364–1379.

- [Ionita-Laza et al., 2011] Ionita-Laza, I., Buxbaum, J. D., Laird, N. M., and Lange, C. (2011). A new testing strategy to identify rare variants with either risk or protective effect on disease. *PLoS genetics*, 7(2):e1001289.
- [Ionita-Laza et al., 2013] Ionita-Laza, I., Lee, S., Makarov, V., Buxbaum, J. D., and Lin, X. (2013). Sequence kernel association tests for the combined effect of rare and common variants. *Am J Hum Genet*, 92(6):841–853.
- [Ionita-Laza et al., 2007] Ionita-Laza, I., McQueen, M. B., Laird, N. M., and Lange, C. (2007). Genomewide weighted hypothesis testing in family-based association studies, with an application to a 100k scan. *The American Journal of Human Genetics*, 81(3):607–614.
- [Kamatani et al., 2010] Kamatani, Y., Matsuda, K., Okada, Y., Kubo, M., Hosono, N., Daigo, Y., Nakamura, Y., and Kamatani, N. (2010). Genome-wide association study of hematological and biochemical traits in a japanese population. *Nat Genet*, 42(3):210–215.
- [Karp et al., 2002] Karp, P. D., Riley, M., Paley, S. M., and Pellegrini-Toole, A. (2002). The metacyc database. *Nucleic acids research*, 30(1):59–61.
- [Kathiresan et al., 2007] Kathiresan, S., Manning, A. K., Demissie, S., D’Agostino, R. B., Surti, A., Guiducci, C., Gianniny, L., Burt, N. P., Melander, O., Orho-Melander, M., Arnett, D. K., Peloso, G. M., Ordovas, J. M., and Cupples, L. A. (2007). A genome-wide association study for blood lipid phenotypes in the framingham heart study. *BMC Med Genet*, 8 Suppl 1:S17.
- [Keating et al., 2008] Keating, B. J., Tischfield, S., Murray, S. S., Bhangale, T., Price, T. S., Glessner, J. T., Galver, L., Barrett, J. C., Grant, S. F., Farlow, D. N., et al. (2008). Concept, design and implementation of a cardiovascular gene-centric 50 k snp array for large-scale genomic association studies. *PloS one*, 3(10):e3583.
- [Kim et al., 2014] Kim, S., Pan, W., and Shen, X. (2014). Penalized regression approaches to testing for quantitative trait-rare variant association. *Frontiers in genetics*, 5.

- [Korn and Whittemore, 1979] Korn, E. L. and Whittemore, A. S. (1979). Methods for analyzing panel studies of acute health effects of air pollution. *Biometrics*, pages 795–802.
- [Kwee et al., 2008] Kwee, L. C., Liu, D., Lin, X., Ghosh, D., and Epstein, M. P. (2008). A powerful and flexible multilocus association test for quantitative traits. *The American Journal of Human Genetics*, 82(2):386–397.
- [Laird and Ware, 1982] Laird, N. M. and Ware, J. H. (1982). Random-effects models for longitudinal data. *Biometrics*, pages 963–974.
- [Lange et al., 2014] Lange, L. A., Hu, Y., Zhang, H., Xue, C., Schmidt, E. M., Tang, Z.-Z., Bizon, C., Lange, E. M., Smith, J. D., Turner, E. H., et al. (2014). Whole-exome sequencing identifies rare and low-frequency coding variants associated with ldl cholesterol. *The American Journal of Human Genetics*, 94(2):233–245.
- [Lee et al., 2012a] Lee, S., Emond, M. J., Bamshad, M. J., Barnes, K. C., Rieder, M. J., Nickerson, D. A., , N. H. L. B. I. G. O. E. S. P.-E. S. P. L. P. T., Christiani, D. C., Wurfel, M. M., and Lin, X. (2012a). Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. *Am J Hum Genet*, 91(2):224–237.
- [Lee et al., 2012b] Lee, S., Wu, M. C., and Lin, X. (2012b). Optimal tests for rare variant effects in sequencing association studies. *Biostatistics*, 13(4):762–775.
- [Li and Leal, 2008] Li, B. and Leal, S. M. (2008). Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. *Am J Hum Genet*, 83(3):311–321.
- [Liang and Zeger, 1986] Liang, K.-Y. and Zeger, S. L. (1986). Longitudinal data analysis using generalized linear models. *Biometrika*, 73(1):13–22.

- [Lin, 2005] Lin, D. (2005). An efficient monte carlo approach to assessing statistical significance in genomic studies. *Bioinformatics*, 21(6):781–787.
- [Lin and Tang, 2011] Lin, D.-Y. and Tang, Z.-Z. (2011). A general framework for detecting disease associations with rare variants in sequencing studies. *The American Journal of Human Genetics*, 89(3):354–367.
- [Litière et al., 2007] Litière, S., Alonso, A., and Molenberghs, G. (2007). Type i and type ii error under random-effects misspecification in generalized linear mixed models. *Biometrics*, 63(4):1038–1044.
- [Liu and Leal, 2010] Liu, D. J. and Leal, S. M. (2010). A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. *PLoS Genet*, 6(10):e1001156.
- [Liu et al., 2007] Liu, Q., Dinu, I., Adewale, A. J., Potter, J. D., and Yasui, Y. (2007). Comparative evaluation of gene-set analysis methods. *BMC Bioinformatics*, 8:431.
- [Luo et al., 2011] Luo, L., Boerwinkle, E., and Xiong, M. (2011). Association studies for next-generation sequencing. *Genome research*, 21(7):1099–1108.
- [Luo et al., 2010] Luo, L., Peng, G., Zhu, Y., Dong, H., Amos, C. I., and Xiong, M. (2010). Genome-wide gene and pathway analysis. *European Journal of Human Genetics*, 18(9):1045–1053.
- [Luo et al., 2012a] Luo, L., Zhu, Y., and Xiong, M. (2012a). Quantitative trait locus analysis for next-generation sequencing with the functional linear models. *Journal of medical genetics*, 49(8):513–524.
- [Luo et al., 2012b] Luo, L., Zhu, Y., and Xiong, M. (2012b). Smoothed functional principal component analysis for testing association of the entire allelic spectrum of genetic variation. *European Journal of Human Genetics*, 21(2):217–224.

- [Lynch et al., 1998] Lynch, M., Walsh, B., et al. (1998). Genetics and analysis of quantitative traits.
- [Madsen and Browning, 2009] Madsen, B. E. and Browning, S. R. (2009). A groupwise association test for rare mutations using a weighted sum statistic. *PLoS Genet*, 5(2):e1000384.
- [Mardis, 2008] Mardis, E. R. (2008). Next-generation dna sequencing methods. *Annu. Rev. Genomics Hum. Genet.*, 9:387–402.
- [McCarthy et al., 2008] McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., and Hirschhorn, J. N. (2008). Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat Rev Genet*, 9(5):356–369.
- [Medina et al., 2009] Medina, I., Montaner, D., Bonifaci, N., Pujana, M. A., Carbonell, J., Tarraga, J., Al-Shahrour, F., and Dopazo, J. (2009). Gene set-based analysis of polymorphisms: finding pathways or biological processes associated to traits in genome-wide association studies. *Nucleic acids research*, 37(suppl 2):W340–W344.
- [Melville et al., 2012] Melville, S. A., Buross, J., Parrado, A. R., Vardarajan, B., Logue, M. W., Shen, L., Risacher, S. L., Kim, S., Jun, G., DeCarli, C., et al. (2012). Multiple loci influencing hippocampal degeneration identified by genome scan. *Annals of neurology*, 72(1):65–75.
- [Metzker, 2009] Metzker, M. L. (2009). Sequencing technologies the next generation. *Nature Reviews Genetics*, 11(1):31–46.
- [Morgenthaler and Thilly, 2007] Morgenthaler, S. and Thilly, W. G. (2007). A strategy to discover genes that carry multi-allelic or mono-allelic risk for common diseases: a cohort allelic sums test (cast). *Mutat Res*, 615(1-2):28–56.
- [Nam et al., 2010] Nam, D., Kim, J., Kim, S.-Y., and Kim, S. (2010). Gsa-snp: a general approach for gene set analysis of polymorphisms. *Nucleic acids research*, page gkq428.



- [Nam and Kim, 2008] Nam, D. and Kim, S.-Y. (2008). Gene-set approach for expression pattern analysis. *Brief Bioinform*, 9(3):189–197.
- [Neale et al., 2011] Neale, B. M., Rivas, M. A., Voight, B. F., Altshuler, D., Devlin, B., Orho-Melander, M., Kathiresan, S., Purcell, S. M., Roeder, K., and Daly, M. J. (2011). Testing for an unusual distribution of rare variants. *PLoS genetics*, 7(3):e1001322.
- [Neyman, 1937] Neyman, J. (1937). Smooth test for goodness of fit. *Scandinavian Actuarial Journal*, 1937(3-4):149–199.
- [Nishimura, 2001] Nishimura, D. (2001). Biocarta. *Biotech Software & Internet Report: The Computer Software Journal for Scient*, 2(3):117–120.
- [O’Dushlaine et al., 2009] O’Dushlaine, C., Kenny, E., Heron, E. A., Segurado, R., Gill, M., Morris, D. W., and Corvin, A. (2009). The snp ratio test: pathway analysis of genome-wide association datasets. *Bioinformatics*, 25(20):2762–2763.
- [Ogata et al., 1999] Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., and Kanehisa, M. (1999). Kegg: Kyoto encyclopedia of genes and genomes. *Nucleic acids research*, 27(1):29–34.
- [Oualkacha et al., 2013] Oualkacha, K., Dastani, Z., Li, R., Cingolani, P. E., Spector, T. D., Hammond, C. J., Richards, J. B., Ciampi, A., and Greenwood, C. M. T. (2013). Adjusted sequence kernel association test for rare variants controlling for cryptic and family relatedness. *Genet Epidemiol*, 37(4):366–376.
- [Pan, 2001] Pan, W. (2001). On the robust variance estimator in generalised estimating equations. *Biometrika*, 88(3):901–906.
- [Pan, 2009] Pan, W. (2009). Asymptotic tests of association with multiple snps in linkage disequilibrium. *Genetic epidemiology*, 33(6):497–507.

- [Pan et al., 2009] Pan, W., Han, F., and Shen, X. (2009). Test selection with application to detecting disease association with multiple snps. *Human heredity*, 69(2):120–130.
- [Pan et al., 2014] Pan, W., Kim, J., Zhang, Y., Shen, X., and Wei, P. (2014). A powerful and adaptive association test for rare variants. *Genetics*, pages genetics–114.
- [Pan and Shen, 2011] Pan, W. and Shen, X. (2011). Adaptive tests for association analysis of rare variants. *Genet Epidemiol*, 35(5):381–388.
- [Peloso et al., 2014] Peloso, G. M., Auer, P. L., Bis, J. C., Voorman, A., Morrison, A. C., Stitzel, N. O., Brody, J. A., Khetarpal, S. A., Crosby, J. R., Fornage, M., et al. (2014). Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. *The American Journal of Human Genetics*, 94(2):223–232.
- [Peng et al., 2009] Peng, G., Luo, L., Siu, H., Zhu, Y., Hu, P., Hong, S., Zhao, J., Zhou, X., Reville, J. D., Jin, L., et al. (2009). Gene and pathway-based second-wave analysis of genome-wide association studies. *European Journal of Human Genetics*, 18(1):111–117.
- [Pinto et al., 2010] Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, J., Magalhaes, T. R., Correia, C., Abrahams, B. S., Almeida, J., Bacchelli, E., Bader, G. D., Bailey, A. J., Baird, G., Battaglia, A., Berney, T., Bolshakova, N., Bölte, S., Bolton, P. F., Bourgeron, T., Brennan, S., Brian, J., Bryson, S. E., Carson, A. R., Casallo, G., Casey, J., Chung, B. H. Y., Cochrane, L., Corsello, C., Crawford, E. L., Crossett, A., Cytrynbaum, C., Dawson, G., de Jonge, M., Delorme, R., Drmic, I., Duketis, E., Duque, F., Estes, A., Farrar, P., Fernandez, B. A., Folstein, S. E., Fombonne, E., Freitag, C. M., Gilbert, J., Gillberg, C., Glessner, J. T., Goldberg, J., Green, A., Green, J., Guter, S. J., Hakonarson, H., Heron, E. A., Hill, M., Holt, R., Howe, J. L., Hughes, G., Hus, V., Igliozzi, R., Kim, C., Klauck, S. M., Klevzon, A., Korvatska, O., Kustanovich, V., Lajonchere, C. M., Lamb, J. A., Laskawiec, M., Leboyer, M., Le Couteur, A., Leventhal, B. L.,

Lionel, A. C., Liu, X.-Q., Lord, C., Lotspeich, L., Lund, S. C., Maestrini, E., Mahoney, W., Mantoulan, C., Marshall, C. R., McConachie, H., McDougale, C. J., McGrath, J., McMahon, W. M., Merikangas, A., Migita, O., Minshew, N. J., Mirza, G. K., Munson, J., Nelson, S. F., Noakes, C., Noor, A., Nygren, G., Oliveira, G., Papanikolaou, K., Parr, J. R., Parrini, B., Paton, T., Pickles, A., Pilorge, M., Piven, J., Ponting, C. P., Posey, D. J., Poustka, A., Poustka, F., Prasad, A., Ragoussis, J., Renshaw, K., Rickaby, J., Roberts, W., Roeder, K., Roge, B., Rutter, M. L., Bierut, L. J., Rice, J. P., Salt, J., Sansom, K., Sato, D., Segurado, R., Sequeira, A. F., Senman, L., Shah, N., Sheffield, V. C., Soorya, L., Sousa, I., Stein, O., Sykes, N., Stoppioni, V., Strawbridge, C., Tancredi, R., Tansey, K., Thiruvahindrapduram, B., Thompson, A. P., Thomson, S., Tryfon, A., Tsiantis, J., Van Engeland, H., Vincent, J. B., Volkmar, F., Wallace, S., Wang, K., Wang, Z., Wassink, T. H., Webber, C., Weksberg, R., Wing, K., Wittemeyer, K., Wood, S., Wu, J., Yaspan, B. L., Zurawiecki, D., Zwaigenbaum, L., Buxbaum, J. D., Cantor, R. M., Cook, E. H., Coon, H., Cuccaro, M. L., Devlin, B., Ennis, S., Gallagher, L., Geschwind, D. H., Gill, M., Haines, J. L., Hallmayer, J., Miller, J., Monaco, A. P., Nurnberger, Jr, J. I., Paterson, A. D., Pericak-Vance, M. A., Schellenberg, G. D., Szatmari, P., Vicente, A. M., Vieland, V. J., Wijsman, E. M., Scherer, S. W., Sutcliffe, J. S., and Betancur, C. (2010). Functional impact of global rare copy number variation in autism spectrum disorders. *Nature*, 466(7304):368–372.

[Price et al., 2010] Price, A. L., Kryukov, G. V., de Bakker, P. I. W., Purcell, S. M., Staples, J., Wei, L.-J., and Sunyaev, S. R. (2010). Pooled association tests for rare variants in exon-resequencing studies. *Am J Hum Genet*, 86(6):832–838.

[Price et al., 2006] Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., and Reich, D. (2006). Principal components analysis corrects for stratification in genome-wide association studies. *Nature genetics*, 38(8):904–909.

[Purcell et al., 2007] Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A.,

- Bender, D., Maller, J., Sklar, P., De Bakker, P. I., Daly, M. J., et al. (2007). Plink: a tool set for whole-genome association and population-based linkage analyses. *The American Journal of Human Genetics*, 81(3):559–575.
- [Sabatti et al., 2008] Sabatti, C., Service, S. K., Hartikainen, A.-L., Pouta, A., Ripatti, S., Brodsky, J., Jones, C. G., Zaitlen, N. A., Varilo, T., Kaakinen, M., et al. (2008). Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. *Nature genetics*, 41(1):35–46.
- [Schaefer et al., 2009] Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., and Buetow, K. H. (2009). Pid: the pathway interaction database. *Nucleic acids research*, 37(suppl 1):D674–D679.
- [Seaman and Müller-Myhsok, 2005] Seaman, S. and Müller-Myhsok, B. (2005). Rapid simulation of p values for product methods and multiple-testing adjustment in association studies. *The American Journal of Human Genetics*, 76(3):399–408.
- [Sham and Purcell, 2014] Sham, P. C. and Purcell, S. M. (2014). Statistical power and significance testing in large-scale genetic studies. *Nat Rev Genet*, 15(5):335–346.
- [Shendure and Ji, 2008] Shendure, J. and Ji, H. (2008). Next-generation dna sequencing. *Nature biotechnology*, 26(10):1135–1145.
- [Shete et al., 2004] Shete, S., Beasley, T. M., Etzel, C. J., Fernández, J. R., Chen, J., Allison, D. B., and Amos, C. I. (2004). Effect of winsorization on power and type 1 error of variance components and related methods of qtl detection. *Behavior genetics*, 34(2):153–159.
- [Silver et al., 2012] Silver, M., Janousova, E., Hua, X., Thompson, P. M., and Montana, G. (2012). Identification of gene pathways implicated in alzheimer’s disease using longitudinal imaging phenotypes with sparse regression. *NeuroImage*, 63(3):1681–1694.

- [Song et al., 2013] Song, P., Xue, J., and Li, Z. (2013). Simulation of longitudinal exposure data with variance-covariance structures based on mixed models. *Risk Anal*, 33(3):469–479.
- [Subramanian et al., 2005] Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America*, 102(43):15545–15550.
- [Sul et al., 2011] Sul, J. H., Han, B., He, D., and Eskin, E. (2011). An optimal weighted aggregated association test for identification of rare variants involved in common diseases. *Genetics*, 188(1):181–188.
- [Sun et al., 2013] Sun, J., Zheng, Y., and Hsu, L. (2013). A unified mixed-effects model for rare-variant association in sequencing studies. *Genetic epidemiology*, 37(4):334–344.
- [Tintle et al., 2011] Tintle, N., Aschard, H., Hu, I., Nock, N., Wang, H., and Pugh, E. (2011). Inflated type i error rates when using aggregation methods to analyze rare variants in the 1000 genomes project exon sequencing data in unrelated individuals: summary results from group 7 at genetic analysis workshop 17. *Genetic epidemiology*, 35(S1):S56–S60.
- [Tsay, 1984] Tsay, R. S. (1984). Regression models with time series errors. *Journal of the American Statistical Association*, 79(385):118–124.
- [Voight et al., 2012] Voight, B. F., Kang, H. M., Ding, J., Palmer, C. D., Sidore, C., Chines, P. S., Burt, N. P., Fuchsberger, C., Li, Y., Erdmann, J., et al. (2012). The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. *PLoS genetics*, 8(8):e1002793.
- [Wang et al., 2012] Wang, H., Nie, F., Huang, H., Yan, J., Kim, S., Nho, K., Risacher, S. L., Saykin, A. J., Shen, L., et al. (2012). From phenotype to genotype: an association study

- of longitudinal phenotypic markers to alzheimer’s disease relevant snps. *Bioinformatics*, 28(18):i619–i625.
- [Wang et al., 2007] Wang, K., Li, M., and Bucan, M. (2007). Pathway-based approaches for analysis of genomewide association studies. *The American Journal of Human Genetics*, 81(6):1278–1283.
- [Wang et al., 2010a] Wang, K., Li, M., and Hakonarson, H. (2010a). Analysing biological pathways in genome-wide association studies. *Nat Rev Genet*, 11(12):843–854.
- [Wang et al., 2010b] Wang, K., Li, M., and Hakonarson, H. (2010b). Annovar: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic acids research*, 38(16):e164–e164.
- [Wang and Elston, 2007] Wang, T. and Elston, R. C. (2007). Improved power by use of a weighted score test for linkage disequilibrium mapping. *The american journal of human genetics*, 80(2):353–360.
- [Wang et al., 2005] Wang, W. Y., Barratt, B. J., Clayton, D. G., and Todd, J. A. (2005). Genome-wide association studies: theoretical and practical concerns. *Nature Reviews Genetics*, 6(2):109–118.
- [Wang et al., 2013] Wang, X., Lee, S., Zhu, X., Redline, S., and Lin, X. (2013). Gee-based snp set association test for continuous and discrete traits in family-based association studies. *Genetic epidemiology*, 37(8):778–786.
- [WARE et al., 1990] WARE, J. H., DOCKERY, D. W., LOUIS, T. A., XU, X., FERRIS, B. G., and SPEIZER, F. E. (1990). Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. *American journal of epidemiology*, 132(4):685–700.

- [Wedderburn, 1974] Wedderburn, R. W. (1974). Quasi-likelihood functions, generalized linear models, and the gauss—newton method. *Biometrika*, 61(3):439–447.
- [Wei et al., 2012] Wei, P., Tang, H., and Li, D. (2012). Insights into pancreatic cancer etiology from pathway analysis of genome-wide association study data. *PloS one*, 7(10):e46887.
- [Weng et al., 2011] Weng, L., Macciardi, F., Subramanian, A., Guffanti, G., Potkin, S. G., Yu, Z., and Xie, X. (2011). Snp-based pathway enrichment analysis for genome-wide association studies. *BMC Bioinformatics*, 12:99.
- [Wu et al., 2010] Wu, M. C., Kraft, P., Epstein, M. P., Taylor, D. M., Chanock, S. J., Hunter, D. J., and Lin, X. (2010). Powerful snp-set analysis for case-control genome-wide association studies. *Am J Hum Genet*, 86(6):929–942.
- [Wu et al., 2011] Wu, M. C., Lee, S., Cai, T., Li, Y., Boehnke, M., and Lin, X. (2011). Rare-variant association testing for sequencing data with the sequence kernel association test. *Am J Hum Genet*, 89(1):82–93.
- [Xu et al., 2014] Xu, Z., Shen, X., Pan, W., Initiative, A. D. N., et al. (2014). Longitudinal analysis is more powerful than cross-sectional analysis in detecting genetic association with neuroimaging phenotypes. *PloS one*, 9(8):e102312.
- [Yandell et al., 2011] Yandell, M., Huff, C., Hu, H., Singleton, M., Moore, B., Xing, J., Jorde, L. B., and Reese, M. G. (2011). A probabilistic disease-gene finder for personal genomes. *Genome research*, 21(9):1529–1542.
- [Ye and Engelman, 2011] Ye, K. Q. and Engelman, C. D. (2011). Detecting multiple causal rare variants in exome sequence data. *Genet Epidemiol*, 35 Suppl 1:S18–S21.
- [Yu et al., 2009] Yu, K., Li, Q., Bergen, A. W., Pfeiffer, R. M., Rosenberg, P. S., Caporaso, N., Kraft, P., and Chatterjee, N. (2009). Pathway analysis by adaptive combination of p-values. *Genetic epidemiology*, 33(8):700–709.

- [Zeger and Liang, 1986] Zeger, S. L. and Liang, K.-Y. (1986). Longitudinal data analysis for discrete and continuous outcomes. *Biometrics*, pages 121–130.
- [Zeger et al., 1988] Zeger, S. L., Liang, K.-Y., and Albert, P. S. (1988). Models for longitudinal data: a generalized estimating equation approach. *Biometrics*, pages 1049–1060.
- [Zeger et al., 1985] Zeger, S. L., Liang, K.-Y., and Self, S. G. (1985). The analysis of binary longitudinal data with time independent covariates. *Biometrika*, 72(1):31–38.
- [Zeger and Qaqish, 1988] Zeger, S. L. and Qaqish, B. (1988). Markov regression models for time series: a quasi-likelihood approach. *Biometrics*, pages 1019–1031.
- [Zhang et al., 2010a] Zhang, K., Cui, S., Chang, S., Zhang, L., and Wang, J. (2010a). i-gsea4gwas: a web server for identification of pathways/gene sets associated with traits by applying an improved gene set enrichment analysis to genome-wide association study. *Nucleic acids research*, 38(suppl 2):W90–W95.
- [Zhang et al., 2010b] Zhang, L., Pei, Y.-F., Li, J., Papasian, C. J., and Deng, H.-W. (2010b). Efficient utilization of rare variants for detection of disease-related genomic regions. *PLoS one*, 5(12):e14288.
- [Zhang et al., 2011] Zhang, Q., Irvin, M. R., Arnett, D. K., Province, M. A., and Borecki, I. (2011). A data-driven method for identifying rare variants with heterogeneous trait effects. *Genetic epidemiology*, 35(7):679–685.
- [Zhang et al., 2014] Zhang, Y., Xu, Z., Shen, X., and Pan, W. (2014). Testing for association with multiple traits in generalized estimation equations, with application to neuroimaging data. *NeuroImage*, 96:309–325.
- [Zhong et al., 2010] Zhong, H., Yang, X., Kaplan, L. M., Molony, C., and Schadt, E. E. (2010). Integrating pathway analysis and genetics of gene expression for genome-wide association studies. *The American Journal of Human Genetics*, 86(4):581–591.



- [Zhou et al., 2010] Zhou, H., Sehl, M. E., Sinsheimer, J. S., and Lange, K. (2010). Association screening of common and rare genetic variants by penalized regression. *Bioinformatics*, 26(19):2375.
- [Zhu et al., 2010] Zhu, X., Feng, T., Li, Y., Lu, Q., and Elston, R. C. (2010). Detecting rare variants for complex traits using family and unrelated data. *Genetic epidemiology*, 34(2):171–187.